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Abstract 
Prostate cancer (PCa) is the most commonly diagnosed cancer in Australian men.  Unfortunately, 
treatment options are limited once the disease progresses to advanced stages.  To develop an 
effective treatment, it is necessary to better understand the molecular mechanisms underlying the 
development of PCa.  The aim of the current study was to investigate the role of intestinal cell kinase 
(ICK), a protein recently found to be upregulated in prostate tumours.  Initially the levels of ICK 
mRNA were examined in two non-tumorigenic human prostate epithelial cell lines and six human 
PCa cell lines with qRT-PCR.  Consistent with the results reported previously, ICK mRNA was 
upregulated in the PCa cell lines when compared to the non-tumorigenic prostate epithelial cells.  
Increased ICK expression in PCa was confirmed by Western blot analyses.  ICK protein was located 
within the cytoplasm and nuclei by immunofluorescence.  siRNA-mediated gene knockdown 
suppressed endogenous expression of ICK mRNA and protein.  Western blot analysis of expression of 
a group of proteins known to regulate cancer cell growth revealed that the level of many of these 
proteins was not changed following manipulation of ICK expression but knockdown of ICK resulted in 
downregulation of epidermal growth factor receptor (EGFR) mRNA and protein levels in C4-2B cells.  
Overexpression of ICK mRNA and protein following transfection of an expression vector was 
confirmed by qRT-PCR and Western blot analyses.  ICK overexpression resulted in increased levels of 
EGFR mRNA and protein expression.  Transfection of C4-2B cells with a construct of a luciferase 
reporter gene driven by the EGFR promoter and measurement of luciferase activity indicated that 
ICK upregulated EGFR promoter activity.  Similarly, overexpression of ICK in a non-tumorigenic 
prostate epithelial cell line, HPr-1, was found to induce EGFR expression, and was associated with an 
increase in the number of mitotic cells, suggesting that ICK may regulate the growth of prostate cells 
through upregulation of the EGFR signalling pathway.  Interestingly, in PCa cells, knockdown of ICK 
expression was found to induce cellular apoptosis, as evidenced by the increase in annexin V positive 
cells and the induction of cleavage of poly-ADP-ribose polymerase-1 (PARP-1).  Examination of pro-
apoptotic proteins confirmed that ICK knockdown induces the protein expression of p53 and its 
downstream target, p21.  These findings provide strong evidence that ICK regulates PCa cell survival 
through modulation of the p53/p21 pathway. 
Taken together, the current study not only identified two novel ICK-downstream targets in PCa cells, 
but also demonstrated, for the first time, the important role of ICK in PCa cell survival.  Thus, these 
findings will provide a basis for further investigation of ICK as a potential therapeutic target for the 
treatment of PCa. 
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Chapter 1.0  General introduction and aims of project 
Although the prostate was first described by the Venetian anatomist Niccolò Massa in 1536, and 
illustrated by Flemish anatomist Andreas Vesalius in 1538, prostate cancer (PCa) was not identified 
until 1853.  Globally, it is the second most common cause of cancer and the fifth leading cause of 
cancer-related death in men.  In 2012 it occurred in 1.1 million men and caused 307,000 deaths.  It 
was the most common cancer in males in 84 countries (Baade PD, 2013).  Although mortality rates in 
Western societies are relatively low compared to incidence, the mortality can be as high as 50% 
within 10 years of first symptoms in countries without sophisticated medicine (Baade PD, 2013). 
Much of the increased understanding of the pathobiology of PCa has been made possible by the 
development of a simple blood test to detect prostate-specific antigen (PSA).  The efficacy of various 
PCa treatments have been defined by PSA studies in large numbers of patients.  Localised prostate 
cancer is treated with surgery and salvage radiotherapy.  Metastatic PCa is treated with anti-
androgen therapy that is only effective for about 2 years, after which time the cancer becomes 
castration resistant prostate cancer (CRPC).  In the final stages of cancer development, 
chemotherapy is the preferred treatment but is only effective for approximately 9 months (De 
Marzo et al., 2004). 
The absence of reliable treatment options for advanced disease has led to research into the 
mechanisms behind PCa development and progression.  A number of protein kinase family members 
have been implicated in PCa (Normanno et al., 2006).  In addition, the epidermal growth factor 
receptor (EGFR) has been shown to promote PCa cell proliferation and survival.  In PCa, expression 
of EGFR has been shown to correlate with Gleason score and can be upregulated in low androgen 
environments (Traish and Morgentaler, 2009).  Protein kinases downstream of EGFR signal 
transduction, such as Raf and mitogen activated protein kinase kinase (MAPKK) have been shown to 
be overexpressed in PCa (Mukherjee et al., 2011) further suggesting that protein kinase signalling 
cascades are aberrantly activated in PCa. 
Recently, we and other laboratories (Whitworth et al., 2012) have empolyed small inteference RNA 
(siRNA)-based high-throughput genetic screening to identify novel protein kinases that play key roles 
in the development and progression of PCa.  Similar to Whitworth et al. (2012) our lab identified the 
Intestinal Cell Kinase (ICK) as one of the key protein kinases essential for the growth of PCa cells 
(unpublished data).  ICK is a ubiquitously expressed serine/threonine protein kinase which, when 
expression is reduced, has shown to reduce cell proliferation in intestinal epithelial cells.  In both 
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studies, ICK was found to be upregulated in PCa.  However the underlying mechanism of action of 
ICK in PCa cells is largely unknown.  Thus, the overall aim of the current study was to investigate the 
downstream mechanisms underlying the functions of ICK in PCa cells with the future intention of 
applying any new knowledge to the development of new PCa therapies. 
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Chapter 2.0 Literature review 
2.1 Prostate Cancer Risk factors    
2.1.1 Incidence 
Prostate cancer (PCa) is the most commonly diagnosed cancer in Australian men.  In 2008, 15% of 
the estimated 900,000 cases worldwide were diagnosed in Australia (Baade PD, 2013).  According to 
the Australian Institute of Health and Welfare, 21,808 new cases were diagnosed in 2009 and in 
2011 approximately 3,000 men died from the disease (Ellis et al., 2013).  By 2020 the number of new 
cases is expected to reach 25,000 per annum.  From 1982-2009, the age-standardised incidence 
increased from 79 to 194 cases per 100,000 males.  This rise has been attributed to more 
comprehensive screening processes (Threlfall et al., 1998) and a 23% increase in health-care 
expenditure from 2005 to 2008 (Ellis et al., 2013).  However, over this period there was a decline in 
mortality from PCa in Australia from 34 deaths per 100,000 in 1982 to 31 per 100,000 in 2011 (Ellis 
et al., 2013).  The decrease was more pronounced in urban compared to rural areas.  Notably, 
between 1998 and 2002 there were 110 extra deaths in rural areas compared to capital cities (Coory 
and Baade, 2005).  Furthermore, indigenous Australians are less likely to be diagnosed and more 
likely to die from PCa (Ellis et al., 2013). 
From 2006-2010, there was a 92% survival rate 5 years following diagnosis, an increase from 59% in 
1986.  In comparison, the 5 year survival rate of men following diagnosis of other cancers is 65% 
(Ellis et al., 2013).  In 2008 the mortality-to-incidence ratio in Australia (0.1) was lower than the 
world (0.8) but similar to that in New Zealand and North America (Ellis et al., 2013).  The lower 
mortality rate from PCa compared to other cancers reflects the multifaceted nature of the disease.  
The fact that different ethnic groups are more at risk of presenting with advance disease (for 
example, indigenous Australians) may reflect differences in screening rates between socioeconomic 
groups and/or an inheritability component of PCa. 
2.1.2 Family history 
There are currently only a few reliable risk factors for PCa namely; family history, race and age.  Men 
with a father or brother with PCa have double the risk of developing the disease compared to men 
without an affected first degree relative.  The risk increases further in men with several affected 
relatives particularly if these relatives are under 60 years of age (Brawley, 2012).  The highest hazard 
ratio (23) has been observed in men with three affected brothers who were diagnosed before the 
age of 60 (Hemminki, 2012).  Hemminki (2012) found a significantly higher hazard ratio in offspring 
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of parents with fatal disease.  Similarly, Jansson et al. (2012) found a higher standardised incidence 
ratio (4.0) in men with brothers diagnosed with high grade tumours compared to men with brothers 
affected by low grade tumours.  A Swedish cohort study found a higher standardised incidence ratio 
among men between the ages of 45 to 49 compared to those aged over 80 years of age (Damber et 
al., 1998).  Moreover, several studies have observed an increased risk in men with a first degree 
female relative with breast cancer (Bostwick et al., 2004).  Rodriguez et al. (1998) found a higher 
incidence rate ratio (1.16) of fatal PCa among men with a family history of breast cancer.  The 
incidence rate ratio increased to 1.65 among men younger than 65 years of age with a female 
relative diagnosed with breast cancer before the age of 50.  The highest rate ratio was among Jewish 
men (1.73) with a family history of breast cancer (Rodriguez et al., 1998).  It is important to note that 
the higher incidence among families may be partly influenced by detection bias, for instance men 
with relatives with cancer may be more likely to undergo screening processes.  However, the high 
incidence among families could also suggest a genetic component to the disease. 
2.1.3 Ethnicity and inheritability 
African-Americans have the highest incidence of PCa.  Between 1988 and 1992, race-specific 
incidence rates in the United States were 135 per 100,000 for Caucasian Americans and 181 for 
African-Americans (Bostwick et al., 2004).  Additionally, African-Americans present with cancers at a 
relatively advanced stage and have a higher stage-specific mortality (Bostwick et al., 2004, Hoffman 
et al., 2001).  African-American and Hispanic men are diagnosed younger than Caucasian men 
(Cotter et al., 2002).  Although these differences may reflect a different genetic background, it may 
be that African-American men have a higher risk of developing the disease because of lifestyle 
factors, such as diet.  This suggestion is supported by Cunningham et al.  (2003) who compared the 
incidence of PCa in first degree family members of African-Americans with that in Caucasian men 
and showed a similar familial aggregation. 
Despite an obvious inheritable component of the disease in some individuals and the varying 
incidence between races, no genetic variation has been identified as a direct causal link with 
development of PCa.  However, a number of genes have been identified where mutations are 
associated with an increased susceptibility.  Carriers of mutations in the breast cancer susceptibility 
genes BRCA1 or BRCA2 have an increased risk of developing early-onset PCa.  For instance, a 
population-based study of 596 PCa patients in Iceland found that the 30 individuals identified as 
carriers of BRCA2 mutations had a lower mean age of diagnosis, more advance tumours, higher 
tumour grade and shorter median survival time (Tryggvadottir et al., 2007).  Similarly, mutation in 
BRCA1 is associated with a moderate increase in PCa risk (Thompson et al.  2002).  Furthermore, PCa 
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tissue from men with either BRCA1 or 2 mutations has significantly higher Gleason scores compared 
to appropriately matched controls (Mitra et al., 2008). 
Other candidate genetic markers/susceptibility genes include variants on chromosome locus 8q24 in 
men of European decent (Yeager et al., 2007) and several single nucleotide polymorphisms (SNP) 
present in both African-American and European men including, seven SNPs at locus 8q24 and three 
at the kallikrein-related peptidase 3 (KLK3) locus (Bensen et al., 2013).  Three missense mutations in 
the tumour suppressor gene, interferon-induced ribonuclease (RNASEL) have been implicated in 
familial cancers among Finnish, American Caucasians and Japanese men (Alvarez-Cubero et al., 
2013).  In an extensive study, men with PCa were significantly more likely to carry germline 
mutations in the homeobox 13 (HOXB13) gene, which encodes a transcription factor involved in 
urogenital development.  Meanwhile, the highest rates of HOXB13 mutations were among men with 
a positive family history of PCa.  This suggests that HOXB13 mutation is conserved within families 
(Ewing et al., 2012). 
2.1.4 Additional inheritability factors 
Two major approaches have been used to identify PCa-related genes and potential modifications of 
structure and function associated with PCa.  Somatic alterations have been identified by 
comparative genomic hybridization as gains or losses of a number of chromosomal regions (Taylor et 
al., 2010).  These include NKX3.1 at 8p21, MYC at 8q24, and PTEN at 10q23.   
A second approach has attempted to identify genetic susceptibility loci for PCa, traditionally by 
analysis of susceptible families and more recently by genome-wide association studies (GWAS). 
Familial studies identified the RNASEL (HPC1) locus which encodes an endoribonuclease for ssRNA 
and is associated with defence against viral infection and ELAC (HPC2), a gene of uncertain function 
(Carpten et al., 2002).  
Genome-wide association studies have identified numerous single-nucleotide polymorphisms (SNPs) 
that are associated with cancer risk (Kader et al., 2009).  These studies identified sequence 
polymorphisms associated with increased cancer risk at the NKX3.1 locus and a major locus proximal 
to MYC (Gelmann et al., 2002) emphasizing the potential importance of these genes initially 
identified by somatic studies.   
In mouse models, loss of function of the homeobox gene, NKX3.1, leads to deregulated expression of 
oxidative damage response genes, increased levels of DNA adducts and tumourigenesis (Ouyang et 
al., 2005).  Conversely gain of function is protective against DNA damage in PCa cell lines (Bowen and 
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Gelmann, 2010).  Since NKX3.1 is frequently down-regulated in human PCa, its inactivation may 
allow accumulation of DNA damage associated with cancer initiation (Bowen et al., 2000).  NKX3.1 
has been shown to be a critical regulator of prostate epithelial differentiation and appears to protect 
against DNA damage in the adult (Ouyang et al., 2005, Bowen and Gelmann, 2010).  The gene may 
act as a tumour suppressor gene that acts as a “gatekeeper” gene for PCa initiation (Magee et al., 
2003).  
Amplification of the chromosomal region encompassing the MYC oncogene is common in advanced 
prostate tumours (Sato et al., 1999) and nuclear MYC protein is up-regulated in many carcinomas 
(Gurel et al., 2008).  Functionally, over expression of MYC immortalizes non-tumourigenenic human 
prostate epithelial cells (Gil et al., 2005) and induces an expression signature characterized by down-
regulation of NKX3.1 (Ellwood-Yen et al., 2003).  
A second abnormally expressed transcription factors is created by the TMPRSS2-ERG fusion gene.  
The fusion protein is an N-terminally truncated ERG protein, a member of the ETS family of 
transcription factors under the control of the androgen-responsive promoter of TMPRSS2 an 
androgen-regulated transmembrane serine protease (Tomlins et al., 2005).  Both genes are located 
on chromosome 21.  TMPRSS2-ERG fusions occur in ∼50% in localized PCa (Albadine et al., 2009).  
Gene fusion may be a result of androgen receptor binding which brings the two genes closer 
together and fusion follows DNA damage (Lin et al., 2009).  Although prevalent the functional 
significance in PCa of the TMPRSS2-ERG fusion and other ETS rearrangements (not discussed here) is 
not understood but may be a disruption in differentiation programs or cooperative interactions with 
other transforming elements.  
2.1.5 Age 
Age is one of the strongest factors contributing to PCa incidence.  The prevalence of PCa at autopsy 
in men over 80 is close to 80% across most ethnic groups (Bostwick et al., 2004).  In Australia, 
incidence rates rise sharply after the age of 50 (Baade PD, 2013).  The high incidence of cancer 
among elderly men is most likely related to accumulated damage to the prostate cells caused by 
oxidative stress (Bostwick et al., 2004).  Such damage may result in alteration in the pattern of gene 
expression and initiation of tumourigenesis.  Supporting evidence linking oxidative stress and PCa 
initiation include an inverse correlation in the level of major antioxidant enzymes and levels oxidized 
DNA adducts (Bostwick et al., 2000).  Interestingly polymorphisms in the APE gene encoding the 
APE/Ref1 enzyme, which functions in excision repair, are associated with increased PCa risk (Kelley 
et al., 2001). 
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An important event associated with DNA damage is shortening of the telomere which may lead to 
chromosomal instability and possibly PCa (Meeker et al., 2002).  Although there is limited 
information on the cause and effects of telomere shortening, various strategies to regulate telomere 
length are being investigated as potential therapeutic agents (Asai et al., 2003). 
The build-up of free radicals in the gland over time results in the accumulation of DNA-adducts and 
increases the frequency of DNA breakages and subsequent mutations.  For example, DNA 
hypermethylation in the promoter region of genes encoding Ras association domain-containing 
protein 1 (RASSF1) and retinoic receptor-beta (RAR-beta) has been associated with aging of the 
prostate tissue and is estimated to be involved in 56% of cancers (Damaschke et al., 2013).   
2.1.6 Hormones 
There is weak evidence supporting a role of testosterone in PCa.  Serum testosterone levels of PCa 
patients were found to be equal to or lower than control patients (Bostwick et al., 2004).  
Alternately, a higher level of the biologically active androgen, 5-αdihydroxytestosterone (5αDHT) has 
been implicated in benign prostatic hyperplasia and PCa.  Inhibition of the enzyme 5-α 
dihydroxytestosterone reductase that converts testosterone to 5-αdihydroxytestosterone in 
androgen-dependent tissues has been shown to decrease PCa risk.  For instance, ~18,000 men with 
low levels of the prostatic biomarker, prostate specific antigen (PSA) were randomized to receive a 5 
mg dose of a 5-α dihydroxytestosterone reductase inhibitor (finasteride) or placebo.  A 25% 
reduction in PCa incidence was observed in the finasteride arm relative to the control arm 
(Thompson et al., 2001).  There was, however, an increase in the rate of high-grade tumours among 
the inhibitor arm.  It was suggested that finasteride treatment may either increase the incidence of 
high-grade tumours or improve the accuracy of the PSA test (Violette and Saad, 2012). 
2.1.7 Diet and lifestyle 
Multiple studies have found a positive correlation between dietary fat intake and PCa, however, the 
studies differ in their selection of controls, the definition of fat, such as meat and dairy, and whether 
the studies adjusted for energy intake (Bostwick et al., 2004).  Strom et al. (2008) found a positive 
association with saturated fats, predominantly from animal products, and biochemical recurrence.  
Biochemical recurrence is defined as a level of prostate specific antigen (PSA) > 0.2 ng/mL following 
prostatectomy (Thompson et al., 2013).  Although the study controlled for obesity and other lifestyle 
factors, men who consumed more saturated fat also consumed significantly more calories.  Punnen 
et al. (2011) performed a case control study of the meat consumption of 470 men with aggressive 
PCa and 512 controls.  The group found a positive association between consumption of ground beef 
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and aggressive PCa.  The control group was matched to age, ethnicity and medical institution.  All 
controls were screened for PCa by PSA testing.  In addition, a case control study of 79 men with PCa 
and 187 controls found unsaturated fat consumption to be an important risk factor (Williams C et al. 
(2011).  The group found diets with high omega-6: omega-3 ratios were associated with an increased 
risk of high grade tumours only.  These studies are not intervention studies and rely on information 
collected from the patients via questionnaires, which are highly subjective. 
It is suggested that the antioxidant function of vitamins could be important in inhibiting PCa 
progression (Lawson et al., 2007).  However, there is little evidence to support this.  A large study of 
~290,000 men in America investigated the relationship between multivitamin supplements and PCa 
risk.  The results demonstrated an increase in advanced PCa in those men who reported excessive 
multivitamin use (Lawson et al.  2007).  Low levels of vitamin A, C or carotenes do not appear to be 
risk factors for development of PCa.  Furthermore, diet supplements of vitamin E and selenium, 
singularly or in combination, were not effective in PCa prevention (Klein et al., 2011).  Despite the 
role of vitamin D in inducing immune cell differentiation (Masko et al., 2013), a meta-analysis 
performed by Gilbert et al. (2011) found no significant evidence that vitamin D plays a role in 
preventing PCa development or progression.  Similarly, Shui et al. (2012) performed a case-control 
study and found no significant correlation between plasma vitamin D levels and overall PCa 
incidence, however they did observe that higher plasma concentrations of vitamin D were 
associated with a 57% reduction in the risk of lethal PCa. 
Finally, obesity has been weakly correlated to PCa incidence.  A meta-analysis of 17 studies 
performed by Bergström et al. (2001) found overweight men had a 6% increase in risk of developing 
PCa and obese men had an increase of 12%.  Moreover, a meta-analysis of 31 cohort studies found 
obesity to be a weak risk factor for PCa, more so for advanced disease (MacInnis and English, 2006).  
This was supported by a meta-analysis by Cao and Ma (2011) which associated a 21% increase in risk 
of biochemical recurrence and a 15% higher risk of dying from PCa with body mass index (BMI) 
increases of 5 kg/m2.  Likewise, a population cohort study of over 200,000 men in America found 
higher BMI increases the risk of PCa-specific mortality.  It is important to note that the individual 
studies included in these meta-analyses varied greatly in size, geographical region and there were a 
number of studies that found obesity to be protective against PCa (Allott et al., 2013). 
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2.2 Pathology 
2.2.1 Anatomy 
The tissue of the prostate gland is divided into three glandular zones; the peripheral, central and 
transition and one non-glandular region, the anterior fibromuscular stroma (McNeal, 1981).  The 
zones are surrounded by a fibromuscular capsule (McNeal, 1981) (Figure 2.1).   
   
Figure 2.1.  Left: general anatomy of the prostate in median sagittal view (Howe et al., 2010); Right: zone 
anatomy of the prostate in transverse view (Kutikov et al., 2009). 
The peripheral zone is the major glandular component (65%) and extends posterolaterally and 
anteriorly from the urethra (Fine and Reuter, 2012).  The central zone comprises 30% of the 
glandular tissue and has ducts branching from the mid-prostate to the base.  Finally, the transition 
zone has 5% of the glandular tissue and ducts extending laterally from the urethral wall (Fine and 
Reuter, 2012).  Around 60-70% of tumours occur in the peripheral zone, 24% in transition zone and 
~8% in the central zone (Cohen et al., 2008).  Due to their more anterior location, tumours derived 
from the transition zone are more difficult to detect by digital rectal exam (DRE) than those in the 
peripheral zone (Fine and Reuter, 2012).  Moreover, transition zone tumours are larger in volume 
than peripheral zone tumours, have lower Gleason scores (section 2.2.2) and are more often organ 
confined (Akin et al., 2006).  Central zone tumours have been shown to have more aggressive 
pathological features then either peripheral or transition zone tumours.  Cohen et al. (2008) found 
central zone tumours were more likely to invade into the seminal vesicles and have positive surgical 
margins. 
2.2.2 Gleason Score 
In Australia, patients with elevated PSA levels (section 2.3.1) and a suspicious DRE are sent for 
needle biopsy and the tumours are graded with a Gleason score.  In the Gleason tumour grading 
system, a pathologist assesses the extent of loss of glandular differentiation and the carcinoma cell 
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growth pattern in stained prostate tissue (Figure 2.2, (Humphrey, 2004).  Five basic grades are used 
and assigned to the primary (most ubiquitous cell type) and secondary grade patterns to produce an 
overall score between 2 and 10 (Humphrey, 2004).  Tumours with a grade in the range 2-4 are 
considered low risk, 5-6 moderate risk, 7 intermediate risk and 8 or above are considered aggressive 
(Australia, 2014).   
 
Figure 2.2.  Gleason grading system  (Wikipedia, 2006). 
In addition to Gleason grading, tumours are staged depending on size of the tumour and the extent 
to which the tumour has migrated beyond the prostate gland (Table 2.1, (Australia, 2014). 
 
Tumour stage Histopathology 
1 Tumour is small and confined within the prostate capsule 
2 Tumour is larger, in 2 nodes but is still within the capsule 
3 Tumour cells are present in lymph node or seminal vesicles 
4 Tumour cells are present in bone or organs outside prostate 
Table 2.1.  Summary of prostate cancer tumour staging system used in Australia (Australia, 2014). 
2.2.3 Metastasis 
The PCa metastatic cascade (Figure 2.3) is a multi-step process which is facilitated by altered 
expression of different proteins involved in angiogenesis, apoptosis and cell motility. 
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Figure 2.3.  The metastatic cascade (Msaouel et al., 2008). 
During stage 1 the tumour cells grow rapidly by upregulating growth factor receptors, such as 
epidermal growth factor receptor (EGFR) and resisting apoptosis.  Initially tumour cells receive 
nutrients via diffusion but once the tumour is >1 mm in diameter it requires neoangiogenisis (Arya et 
al., 2006).  Tumour cells stimulate this by upregulating proangiogenic proteins such as vascular 
growth factor or fibroblast growth factor (Arya et al., 2006).  In stage 3, the cells escape from 
prostate by intravasation into the periprostatic fat, the neurovascular bundle or to the outer edge of 
the gland (Kench et al., 2011).  Cancer cells may spread into the seminal vesicle via the ejaculatory 
duct, through the prostatic capsule into the soft tissue and subsequently into the seminal vesicle 
(Ohori et al., 1993).  To decrease cell adhesion, PCa cells downregulate epithelial cadherin, a 
calcium-dependent cell-cell adhesion molecule.  They also alter the expression of integrins, proteins 
that facilitate the interaction between cells and the extracellular matrix (Arya et al., 2006).  Once in 
the general circulation (stage 4) cancer cells must evade the immune system by either 
downregulating the major histocompatibility complex or by travelling as a fibrin clot (Arya et al., 
2006).  PCa cells frequently metastasise to bone, for example lumbar spine, ribs, pelvis or femur 
(Msaouel et al., 2008).  The cells attach to bone via low affinity binding to bone marrow epithelium-
specific lectins and induce firmer adhesion via bone marrow epithelium-specific integrins (Arya et 
al., 2006).  Extravasation by PCa cells is aided by osteoclasts, the bone cells that reabsorb bone 
tissue.  PCa cells activate bone resorption by osteoclasts which results in seeding by the cancer cells 
and the release of growth factors by the surrounding bone tissue (Msaouel et al., 2008).  These 
processes allow for a more stable growth environment for the cancer cells. 
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At every stage of the cascade PCa cells must evade apoptotic signalling.  This requires, for example, 
diminished function of the tumour suppressor gene, the phosphatase and tensin homolog (PTEN) 
and subsequent hyperactivation of antiapoptotic proteins such as protein kinase B (Akt) and B-cell 
lymphoma 2 (Bcl-2) as well as, resistance to signalling from proapoptotic proteins such as the 
apoptosis antigen 1 (FasR) and its ligand, FasL.  PTEN functions to dephosphorylate lipid-signalling 
intermediates and deactivate phosphoinositide 3-kinase (PI3K) signalling, which leads to cell 
proliferation, differentiation and survival.  PI3K signalling activates Akt which leads to inhibition of 
apoptosis (DeMarzo et al., 2003).  Homologous deletion of PTEN occurs in approximately 40% of 
primary PCa (Barbieri et al., 2013).   
The FasR-induced apoptotic pathway is used by cytotoxic T cells as part of the natural immune 
response (Msaouel et al., 2008).  FasR is a member of the tumour necrosis factor family of proteins, 
and when activated leads to Caspase mediated apoptosis and the inhibition of anti-apoptotic 
proteins, Bcl-2 and B-cell lymphoma extra-large (Bcl-xl) (Park et al., 2010).  Soluble FasR, mutation of 
cell-surface FasR or Bcl-2 and Bcl-xl overexpression can lead to suppression of FasR-induced 
apoptosis in PCa (Park et al., 2010). 
 
2.3 Biomarkers for detection and prognosis 
2.3.1 Prostate Specific Antigen 
PCa has no specific symptoms until the tumour becomes large enough to impede normal functioning 
of the urethra.  In Australia, early detection is usually made by DRE and/or measurement of levels of 
serum PSA by immunoassay.  The preliminary diagnosis is followed by a needle biopsy and 
ultrasound (Ellis et al., 2013).  PSA is a 30 kDa glycoprotein secreted into the seminal plasma in large 
concentrations (~0.35 mg/mL) by the prostatic epithelial cells (Lippi et al., 2009).  Its major purpose 
is to cause liquefication of the seminal clot following ejaculation (Hoffman et al., 2001).  PSA is 
encoded by the KLK3 gene, a member of the kallikrein gene family which is regulated through the 
steroid hormone-receptor system (Lilja et al., 2008).  Low concentrations of PSA (0.6 ng/mL) are 
found in the serum of normal males (Lippi et al., 2009).  In PCa, there is disruption of the basement 
membrane resulting in leakage of PSA into the bloodstream (Lilja et al., 2008).  PSA levels are directly 
correlated with age and prostate volume.  For healthy individuals, the levels increase from a median 
concentration of 0.7 ng/mL at 40- 49 years of age to 0.9 ng/ml between 50- 59 (Lippi et al., 2009).  
Patients with benign prostatic hyperplasia (BPH) will also show elevated PSA and, as a result, PSA 
levels cannot be used in isolation for PCa diagnoses.  For example, a multicentre trial of the PSA and 
13 
 
prostate volume values of 4,627 patients with BPH and 179 controls found that men with BPH had 
higher serum PSA (mean 2.6 ng/mL) than the control arm (mean 0.7 ng/mL).  The men in the control 
arm, however, were younger (mean 31 years) than those in the BPH arm (64 years) (Roehrborn et 
al., 1999). 
A PSA concentration of 4 ng/mL or above is commonly used as a threshold for biopsy.  This level has 
a positive predictive value of about 30% in men aged > 50 years of age and a negative predicative 
value of ~85% in men of between 65 and 70 years of age (Hayes and Barry, 2014).  Unfortunately, 
there are no reliable means of distinguishing aggressive and non-aggressive tumours by PSA 
measurement.  In order to improve the predictive capacity of PSA in men with serum PSA 
concentrations between 4-10 ng/mL, the ratio of free PSA (fPSA) versus bound PSA has been trialled.  
Pepe and Aragona (2010) showed a 28.8% PCa detection rate in men with PSA < 10 ng/mL.  
Furthermore, the prostate health index (phi) is a formula that uses a combination of total PSA, fPSA 
and a subform of fPSA, the pro-PSA molecule (p2PSA) (Loeb and Catalona, 2014).  Loeb et al. (2013) 
found men with a high phi were significantly correlated with negative biopsies.  Similarly, a European 
study of ~600 men found that phi was a significantly better predictor of biopsy outcome compared 
to tPSA and fPSA (Lazzeri et al., 2013). 
From 1994 to 2006 there was a decline in PCa mortality in both the USA and the UK (Strope and 
Andriole, 2010).  In a randomised trial to determine the efficacy of biochemical screening in reducing 
mortality in men aged between 55 and 74 years of age, a higher incidence of cancer was detected in 
the PSA screened patients than the control group (7.4% vs 6.2%), but there was no difference in 
cancer-specific mortality (Grubb et al., 2008).  One of the major limitations of this study was that 
only 50% of the control patients had their PSA levels measured.  Moreover, the European 
randomized study of screening for PCa, which involved 182,000 men between the ages of 50 and 74 
across seven countries, found that individuals from the screening group were more likely to be 
diagnosed with cancer and less likely to die than those from the control group (Schroeder et al., 
2009).  In Australia almost 800,000 PSA tests and 17,000 biopsies were performed in 2012, the 
highest number in the 65-74 year age group (Ellis et al., 2013).  Although these studies confirm that 
PSA screening reduces mortality, there is still a risk of over diagnoses and PSA screening should be 
left to the discretion of the individual.  There is also a clear need for improvements in the screening 
processes. 
2.3.2 Circulating tumour cells 
Circulating tumour cells (CTC) are potential biomarkers for advanced stage PCa.  In order to 
metastasise, both primary and metastatic tumours must shed cells into the bloodstream and into 
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the lymphatic circulation.  These CTC can be isolated from peripheral blood or the bone marrow and 
quantitated to assess disease progression (Doyen et al., 2012).  First a CTC enriched fraction is 
isolated then the CTCs are detected using DNA, RNA or protein markers.  CTC are captured from 
peripheral blood using antibodies to epithelial proteins, such as epithelial cell adhesion molecule 
(Saad and Pantel, 2012).  They are distinguished from white blood cells by the antibody capture of 
cell-specific proteins, such as cytokeratins for CTC and the glycoprotein, CD45 for white blood cells 
(Saad and Pantel, 2012).   
CTC typically express PSA, alpha-methyl CoA racemase (AMACR) and exhibit gene-specific genomic 
abnormalities, such as gene copy amplifications (Danila et al., 2011).  A pilot study by Moreno et al.  
(2005) showed that the presence of CTCs in patients with metastatic PCa was associated with short 
survival (<1 year).  Similarly, de Bono et al. (2008) found that monitoring the number of CTCs was a 
better prognostic determinant than measurements of PSA levels post chemotherapy.  A cohort study 
at the Memorial Sloan-Kettering Cancer Centre found that baseline CTC levels in patients 4, 8 and 12 
weeks post-treatment were more strongly correlated to risk of mortality than PSA (Danila et al., 
2007).  Davis et al. (2008) performed a comparison study of PSA and CTC levels on 97 men with 
localised PCa.  The group found no correlation between CTC levels and tumour volume, pathological 
stage or Gleason score.  More recently, a study on the CTC populations in control and patients with 
different stages of PCa found CTC counts were significantly increased in metastatic PCa compared to 
localised cancer but localised cancer CTC counts were at control levels (Friedlander et al., 2014).  The 
relevance of CTC in patients with low grade tumours is still under investigation.   
2.3.3 Histological biomarker, alpha-methylacyl CoA racemase (AMACR)   
With the increase in PSA testing there has been an increase in the number of needle biopsies.  As a 
result, diagnosis of PCa is often left to the discretion of a pathologist.  The difficulty in distinguishing 
minimal adenocarcinomas from BPH (Evans, 2003) prompted the development of specific 
immunohistochemical staining for cancer cells in biopsied specimens.  AMACR is a 382 amino acid 
protein with a primary function related to the β oxidation of branched chain fatty acids, bile acid 
intermediates and trihydroxycholestanoic acid (Evans, 2003).  Microarray and northern blot analysis 
demonstrated unregulated AMACR expression in PCa tissue, whereas expression in normal prostate 
tissue was undetectable (Xu et al., 2000).  The increased levels of AMACR mRNA distinguished 
benign from cancer tissue (Al-Maghrebi et al.,  2012) and positive staining of AMACR was 
significantly correlated with PCa in an extensive population study (Jiang et al. (2013).  Conversely, 
Gumulec et al. (2012) found no significant difference in serum concentration of AMACR in PCa 
patients compared to controls.  When AMACR expression is compared among disease states, it is 
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higher in localised cancer tissue than in metastatic cancer (Rubin et al., 2005).  For instance, in a 
cohort study of 920 men with PCa, weaker AMACR staining was associated with higher PSA and 
more advanced clinical stage at diagnosis (Barry et al., 2012).  These results indicate AMACR has 
utility in distinguishing cancer tissue from enlarged prostatic tissue during biopsy. 
2.3.4 New potential biomarkers 
In the search for more reliable biomarkers, a genetic variant, the TMPRSS2:ERG fusion gene has been 
identified.  Prostate cancer antigen 3 (PCA3) and the prostate health index (phi) have also been 
considered.  Fusions between the androgen-regulated transmembrane protease serine gene 
(TMPRSS2) and E twenty-six (ETS) family of transcription factors were discovered in PCa in 2005 
(Tomlins et al., 2005).  This fusion results in the aberrant expression of the ETS related gene (ERG) 
transcription factor.  The ETS family are involved in many cellular functions, including cell 
proliferation, apoptosis and migration (Tomlins et al., 2009).  The TMPRSS2:ERG is the commonest 
subtype of ETS fusion (~85% of ETS fusion samples) and present in ~50% of tumours (Tomlins et al., 
2009).  They are reasonably rare in BPH.  Population studies suggest that men with TMPRSS2:ERG 
fusion could have more aggressive phenotype, although more evidence is required (Tomlins et al., 
2009).  Leyten et al. (2014) detected urinary TMPRSS2:ERG transcript by real- time polymerase chain 
reaction (RT-PCR) and a showed a 90% specificity and a 94% positive predictive value for PCa 
detection. 
Another emergent biomarker is the transcript of PCA3.  PCA3 is a noncoding RNA that is specific to 
the prostate (Salagierski and Schalken, 2012).  Hessels et al. (2003) found a ~66 fold upregulation of 
the PCA3 transcript in 95% of tumour tissues when compared to BPH.  PCA3 transcripts are 
detectable in urine by RT-PCR and are expressed as a score (PCA3 mRNA/ PSA mRNA x 1000) 
(Salagierski and Schalken, 2012).  The usefulness of PCA3 score as a prognosticator for tumour stage 
is controversial.  Hessels et al. (2010) found no correlation with urine PCA3 score and Gleason score 
or tumour evasion.  Conversely, Nakanishi et al. (2008) observed a lower average PCA3 score for low 
volume tumours following prostatectomy.  These results were supported by Auprich et al. (2011) 
who found lower PCA3 scores with lower grade tumours.  However, there is evidence that PCA3 is a 
good predictor of a requirement for repeat biopsy.  For instance, in a study of 463 patients there was 
a 44% decrease in repeat biopsy when a PCA3 cut off of 20 was used.  Unfortunately, 9% of clinically 
significant cancers were missed (Haese et al., 2008).   
In order to improve the accuracy of PCa diagnosis, a combination of one or more biomarkers could 
be the best prognosticator.  For example, PCA3 score has been used in combination with phi to 
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predict PCa diagnosis and to stratify patients (Ferro et al., 2012).  Combining biomarkers could in 
turn minimise the risk of over diagnosis and unnecessary medical interventions. 
2.4 Therapeutic Options 
2.4.1 Localised disease 
Treatment options for PCa depend greatly on the severity of the tumour.  Patients with early stage 
and localised disease are treated with watchful waiting (WW), active surveillance (AS), radical 
prostatectomy (RP), prostate brachytherapy (PB) or external beam radiation therapy (EBRT) (Keyes 
et al., 2013).  AS is used as a treatment option for patients with tumours that have a Gleason score 
of <6, a tumour stage of <2 and a PSA value of <10 ng/mL (Dall'Era et al., 2012).  Patients are 
biopsied 6-12 months after the initial diagnosis and routinely monitored with PSA testing and follow-
up biopsies (Keyes et al., 2013).  Cancer specific mortality is between 0-1% with AS and about 30% of 
patients will receive further intervention after 2.5 years, usually as a result of changes in cancer 
pathology or an increase in PSA doubling time (Dall'Era et al., 2012).  Older men with <10 years life 
expectancy due to their age or other comorbidities may be recommended for WW independent of 
the tumour aggressiveness.  WW requires DRE and PSA testing every 6-12 months (Freedland, 2011). 
RP is the only surgical option for PCa and is recommended for younger men (<70 years of age) with 
Gleason scores between 6 and 7 and PSA levels >10 ng/mL (Heidenreich et al., 2014a).  Han et al. 
(2003) found that of ~2,000 men that underwent RP, 84% had no biochemical reoccurrence (BCR) 
after 5 years, 72% after 10 years and 61% of men had no BCR after 15 years.  A PSA level of >0.2 
ng/mL several years post prostatectomy is classified as a BCR.  A number of studies have assessed 
whether RP offers a survival advantage over WW.  Bill-Axelson et al.  (2011) assigned 347 men to a 
RP group and 348 to WW.  After 15 years, 55 men (cumulative death incidence 14.4%) in the RP 
group had died from PCa and 81 men in the WW group (cumulative death incidence 20.7%).  The 
significant survival benefit for the RP arm was mostly in men under the age of 65.  Similar results 
were found after > 20 years of follow-up (Bill-Axelson et al., 2014).  Wilt et al. (2012) found that only 
patients with a pre-treatment PSA of >10 ng/mL or high-risk PCa had a significant survival benefit 
following RP; although they were less likely to develop metastases.  Urinary incontinence occurs in a 
significant number of patients (~42%) and may persist for 24 months or longer post RP.  Erectile 
dysfunction may occur in some patients for up to 24 months (Keyes et al., 2013).  These quality of 
life issues should be considered when deciding on treatment options for organ-confined tumours, 
particularly when the patient is 65 years or older.  Conversely, the concept of living with untreated 
cancer may cause anxiety in some patients.  It is therefore important that patients are fully aware of 
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both the risks and benefits of treatment and are encouraged to make an independent decision about 
treatment.   
PB is administered in either low (LDB) or high doses (HDB).  LDB involves permanently implanting 
radioactive seeds into the prostate unlike HDB, in which radioactive sources are administered via 
catheters over a ten minute period (Keyes et al., 2013).  EBRT is a procedure in which X-ray beams 
are aimed at the prostate for a few minutes daily (Australia, 2014).  LDB is recommended as a first-
line treatment in patients that are not eligible for surgery and with a tumour grade < 2, a Gleason 
score < 7 and a PSA level of < 10 ng/mL (Heidenreich et al., 2014a).  The disease-free survival of men 
with low to medium-risk tumours following LDB has been reported to be as high as 97% after 5 years 
and 94% after 10 years (Morris et al., 2013).  EBRT is recommended for patient with high-risk, organ-
confined tumours (Heidenreich et al., 2014a).  Radiation toxicity occurs in <5% but erectile 
dysfunction occurs in ~40% of patients.  A recent multicenter study by Grimm et al. (2012) compared 
the treatment outcomes of patients with low, medium and high risk tumours following RP, EBRT and 
PB.  Interestingly, for low risk patients PB produced the best biochemical free progression, EBRT 
and/or PB for intermediate risk patients and for high risk patients a combination of EBRT and PB with 
or without androgen deprivation therapy compared to any individual treatment. 
2.4.2 Metastatic Stage 
Despite good prognosis for patients treated for localised PCa, about 35% of men will experience an 
increase in PSA 10 years post treatment (Freedland, 2011).  A PSA of >0.2 ng/ml indicates recurrent 
cancer post RP and after PB or EBRT a level of 2 ng/mL above the lowest detected post-therapy PSA 
indicates BCR  (Heidenreich et al., 2014b).  BCR in the bed of prostate following RP may be predicted 
in 80% of patients with a PSA increase of >3 years, a PSA doubling time of >15 months and a Gleason 
score of <7 (Heidenreich et al., 2014b).  Systemic failure is most likely in men with a PSA increase 
after a year, coupled with a doubling time of 4-6 months and Gleason scores > 8 (Heidenreich et al., 
2014b).  Moreover, this aggressive phenotype with two or more affected lymph nodes has been 
associated with cancer specific mortality (Abdollah et al., 2013).   
BCR in the prostate bed is usually treated with salvage radiotherapy with or without androgen 
deprivation therapy (ADT) before PSA reaches 0.5 ng/mL (Heidenreich et al., 2014b).  Salvage 
radiotherapy has been shown to increase PCa survival by as much as three fold compared to 
observation in men with a PSA doubling time <6 months when treatment was initiated within 2 years 
of BCR (Trock et al., 2008).  Similarly, a study of over 2,500 men, 32% of which received salvage 
radiotherapy following BCR, found radiation provided a reduction in disease progression but not in 
overall survival (OS) (Boorjian et al., 2009).  ADT in conjunction with salvage radiotherapy has been 
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shown to increase PSA progression-free rate and decrease cumulative incidence of metastatic PCa 
(Punnen et al., 2013). 
Once the tumour has metastasised men are treated with anti-androgen therapy.  The androgen 
receptor (AR) belongs to the steroid family of receptors.  In the absence of a ligand, the AR is 
contained in the cytoplasm bound to heat shock proteins (Green et al., 2012) but steroid binding 
activates its function as a ligand-dependent transcription factor responsible for the regulation of 
expression of androgen-related genes, such as KLK3 (Knudsen and Penning, 2010).  In PCa it is 
believed to play an important role in cell cycle progression, survival and growth (Green et al., 2012).  
ADT is effective through multiple mechanisms.  Luteinising hormone-releasing hormone (LHRH) 
agonists such as goserelin or leuprolide, are the first line of treatment in ADT (Heidenreich et al., 
2014b).  These agents result in an initial increase in luteinising hormone and testosterone and 
ultimately tumour growth termed the “flare response” (Massard and Fizazi, 2011).  After 
approximately a week, the high testosterone levels negatively feedback on the production of LH and 
consequently testosterone drops to ~5-10% of normal levels.  Recently, LHRH antagonists have been 
explored in order to circumvent the flare response with promising results.  For instance, a study of 
610 men found a LHRH antagonist achieved more rapid testosterone suppression compared to 
leuprolide without a flare response (Klotz et al., 2008). 
Direct androgen antagonists including, bicalutamide, flutamide and nilutamide (Massard and Fizazi, 
2011) work by the recruitment of AR co-repressors (Knudsen and Penning, 2010).  These agents are 
not recommended as a standard monotherapy in the treatment of metastatic disease due to the lack 
of positive clinical outcomes (Heidenreich et al., 2014b).  Drug efficacy is monitored by 
measurement of PSA levels, tumour volume and relief of symptoms.  Side effects of ADT include 
disruption of sexual function, particularly loss of libido and gynecomastia (Violette and Saad, 2012).  
Intermittent ADT therapy is a treatment regime which involves cycling hormone treatment, usually a 
LHRH analogue or antagonist plus a direct androgen antagonist, with periods of no treatment 
(Boccon-Gibod et al., 2007).  It has been shown to improve patient quality of life by reducing the 
severity of the unwanted side effects and is becoming a standard treatment for metastatic PCa 
(Heidenreich et al., 2014b). 
Unfortunately, this line of treatment is only effective for a finite period of time, usually 18-24 
months after which the cancer becomes castration-resistant prostate cancer (CRPC) (Petrylak et al., 
2004).  Subsequently, a rise in PSA level, tumour regrowth and metastatic spread occurs (Knudsen 
and Scher, 2009).  At this stage of tumour progression, the median survival is 10-12 months (Petrylak 
et al., 2004).  It is important to distinguish CRPC from hormone refractory prostate cancer (HRPC) as 
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CRPC is still responsive to secondary hormone treatments whereas HRPC is completely resistant 
(Heidenreich et al., 2014b).  A number of mechanisms for androgen resistance have been identified.  
Firstly, AR amplification occurs in approximately one third of men with CRPC and may be via 
amplification of the gene locus, increased transcription or protein/mRNA stabilisation (Green et al., 
2012).  Mutations in different regions of the AR protein may result in activation of the AR by other 
steroids, AR antagonists or cause increased sensitivity of the AR to DHT (Green et al., 2012).  This 
situation is infrequent among cancer patients (8-25%) (Debes and Tindall, 2004).  Splice variants in 
the ligand binding domain of the AR have also been identified and result in the AR becoming 
constitutively active (Hornberg et al., 2011).  Interestingly, splice variants have not been identified in 
normal prostate tissue (Sun et al., 2010).  Finally, resistance to ADT can be the result of hyper-
activation due to activation by kinases or cofactors (Massard and Fizazi, 2011).  Signal transduction 
by the Ras-Raf-MAP pathway activated by ligands such as, epidermal growth factor (EGF) and insulin 
growth factor (IGF) have been implicated in AR activation in low androgen environments (Green et 
al., 2012).  These pathways have been shown to be upregulated in more aggressive cancers (Yuan 
and Balk, 2009). 
2.4.3.  Castration resistant prostate cancer 
Secondary hormonal therapies, such as abiraterone acetate and MDV3100 and cytotoxic agents, are 
used when primary ADT has failed.  MDV3100 is a competitive AR antagonist which binds with a 
much greater affinity than other antagonists, such as bicalutamide, and inhibits AR translocation to 
the nucleus (Green et al., 2012).  In a small phase I/II study of men with CRPC, MDV3100 led to a PSA 
decrease of >50% in 62% chemotherapy-naive patients and 51% of docetaxel-treated patients (Scher 
et al., 2010).  Phase III trials are still to be published for this treatment option.  Abiraterone acetate is 
a permanent inhibitor of androgen production and can be used before and after chemotherapy has 
failed.  Abiraterone is an inhibitor of cytochrome P450-17 (CYP17) and 17α-hydroxylase.  CYP17 is 
expressed in adrenal and tumour tissue and catalyses the production of progesterone and 
androstenedione which are precursors of testosterone (Barrie et al., 1994).  Attard et al.  (2008) 
performed phase I clinical trials on abiraterone and observed a decrease in PSA concentration in 66% 
of patients.  Phase III trials by de Bono et al.  (2010) with 1,200 men that failed chemotherapy 
treatment compared the OS of patients on abiraterone and prednisone with those treated with 
prednisone alone.  The group reported an average OS of 450 days for the patients on abiraterone 
compared to 332 days for the control patients.  In 2011 the Food and Drug Administration in the 
United States approved this drug for treatment in PCa (Massard and Fizazi, 2011). 
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Chemotherapeutic agents, such as docetaxel, estramustrine, mitoxantrone or cabazitaxel are usually 
used in combination with steroids or AR antagonists (Attard and de Bono, 2011).  Estramustrine, 
mitoxantrone and docetaxel are antineoplastic agents.  Docetaxel binds to β-tubulin thereby 
inhibiting microtubule depolymerisation.  Consequently, cell cycle progression stalls, ultimately 
leading to Bcl-2 inactivation and apoptosis via the Caspase pathway (Ting et al., 2007, Debes and 
Tindall, 2004).  Impaired tubular function also impedes AR translocation through the cell into the 
nucleus thereby reducing transcription of AR regulated genes (Madan, 2011).  This has been 
demonstrated in vitro as docetaxel reduced both AR and PSA expression in PCa cells (Kuroda et al., 
2009).   
One phase III trial of docetaxel and estramustrine by Petrylak et al.  (2004) compared tumour 
progression of two treatment groups.  338 patients were treated with docetaxel and estramustrine 
and 336 received steroid treatment (prednisone) and mitoxantrone.  The median OS was higher for 
the docetaxel and estramustrine group (17.5 months) compared to the mitoxantrone and 
prednisone (15.6 months).  Similarly, the progression time was 6.3 months for the docetaxel group 
and 3.2 months for the mitoxantrone group, however, neutropenic fevers, nausea and 
cardiovascular events were more common in the docetaxel group.  In addition, Tannock et al.  (2004) 
published a randomised phase III trial with 1,006 men across 24 countries.  All men received 5 mg of 
prednisone and were randomly assigned to receive 12 mg of mitoxantrone or 75 mg of docetaxel 
every 3 weeks or 30 mg for 5 of every 6 weeks.  The median survival was 16.5 months in the 
mitoxantrone group, 18.9 months in the docetaxel every 3 weeks group and 17.4 months for the 
group with docetaxel administered weekly.  More men in both docetaxel groups had reductions in 
pain and improvements in quality of life but also experienced more adverse side effects than the 
other groups.  Conversely, phase II trials of docetaxel and doxercalciferol (1α-hydroxyvitamin D2) 
combination therapy showed no improvement in OS or toxicity when compared with docetaxel 
therapy alone (Attia et al., 2008).  Whereas, a double blind study performed by Beer et al.  (2007), 
which assigned 250 patients on docetaxel treatment regimens to 45 µg of 1,25-dihydroxyvitamin D3 
or placebo, reported a 50% reduction in PSA in 58% of patients on the combination therapies 
compared to 49% in the placebo arm.  The adverse effects of docetaxel include, peripheral 
neuropathy, myelosuppresion, arthralgias, myalgias, and skin reactions (Cella et al., 2003).  
Unfortunately, approximately 40% to 50% of CRPC patients have only a 6-9 month response to 
chemotherapy (as assessed by PSA levels) (Mathew and DiPaola, 2007).  In these cases salvage 
chemotherapy is a treatment option.  In a phase II trial of 755 patients with CRPC that had cancer 
progression during or after docetaxel treatment, patients were assigned to receive cabazitaxel plus 
prednisone or mitoxantrone plus prednisone.  The patients in the cabazitaxel arm demonstrated a 
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significant increase in OS, however side effects occurred more frequently (Heidenreich et al., 2014b).  
At this stage of disease progression, palliative care is imperative and new trials of targeted therapies 
should be made known to the patients as they become available.   
 
2.5 Targeted therapy  
2.5.1 Insulin-like growth factor pathway 
Insulin-like growth factor 1 (IGF1) and its receptor, insulin-like growth factor receptor (IGF1R) 
mediate downstream signal transduction pathways, for example, the mitogen activated protein 
kinase (MAPK) and phosphoinositide 3-kinase/protein kinase B (PI3K/Akt).  Activation of these kinase 
pathways results in a suppression of apoptosis, and an increase in cell proliferation, invasion and 
survival (King and Wong, 2012).  The binding of IGF1 to IGF1R results in autophosphorylation in the 
kinase domain of IGF1R and the recruitment of insulin receptor substrate proteins and the 
subsequent phosphorylation of PI3K or MAPK (King and Wong, 2012).  The association between high 
serum IGF-1 concentrations and an increased risk of PCa is controversial (Kojima et al., 2009).  A 
number of studies have reported a positive correlation while others have reported an inverse 
relationship.  Roddam et al. (2008) performed a meta-analysis of 12 studies and found a marginal 
correlation between IGF-1 and PCa.  Immunohistochemical staining of normal, localised and 
metastatic cancer tissue has demonstrated an upregulation of IGF1R in the stroma of prostate tissue 
(Ryan et al., 2007).  Furthermore, IGF-1 has been linked to the AR as IGF-1 promotes AR signalling by 
increasing the expression of AR cofactors, transcriptional mediator 2 protein and insulin degrading 
enzyme (Saraon et al., 2011).  Alternatively, PCa cell lines treated with antiandrogens are unable to 
activate the AR. 
The human monoclonal antibodies figitumumab and cixutummunab, which target the extracellular 
domain of the IGF1R, have been trialled as potential therapies for PCa.  Preoperative treatment with 
figitumumab decreased IGF1R and AR expression as measured by immunohistochemical staining in 
prostatectomy specimens (Chi et al., 2012).  Cixutummunab phase II trials have shown some 
promise.  Disease stabilisation was observed in about a third of men with CRPC receiving regular 
doses, although adverse hyperglycaemia was also reported in some men (Aggarwal et al., 2013).   
2.5.2 Epidermal growth factor receptor 
The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases contain an 
extracellular ligand binding, a transmembrane and an intracellular tyrosine kinase domain (Wang 
and Hung, 2012).  The family contains four members, EGFR/ErbB-1/HER-1, ErbB-2/HER-2/neu, ErbB-
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3/HER-3 and ErbB-4/HER-4.  Ligands of EGFR include, EGF, transforming growth factor α (TGF-α) and 
ampiregulin.  Following ligand binding, EGFR dimerises and activates several downstream kinases, 
such as PI3K, MAPK and phospholipase leading to cellular adhesion, differentiation and proliferation 
(Wang and Hung, 2012).  EGFR is downregulated by androgens in normal prostate tissue and 
castration of mature animals causes a dose-dependent upregulation of EGFR (Traish and 
Morgentaler, 2009).  In PCa, EGF promotes tumour cell motility, adhesion and invasion and is 
antiapoptotic in cell lines overexpressing EGFR (Traish and Morgentaler, 2009).  It has been reported 
to induce the cyclin-dependent kinase (cyclin D1), which is involved in progression though the GI 
phase of the cell cycle (Herbst and Shin, 2002).  EGFR is expressed in primary and secondary tumours 
and expression increases with disease severity.  Di Lorenzo et al. (2002) found 40% of prostatectomy 
biopsy specimens stained for EGFR, that increased to 70% of tissues following treatment with 
hormone therapy and prostatectomy and, finally 100% of tissues from CRPC were EGFR positive.  
Furthermore, EGFR expression was significantly correlated with high Gleason score and higher levels 
of PSA.   
 
In terms of therapies, direct antagonists of EGFR have been developed as well as inhibitors of the 
downstream kinases.  The chimeric anti-EGFR, monoclonal antibody, Cetuximab binds to the 
extracellular domain of EGFR and inhibits EGF from binding (Fu et al., 2012).  It has been shown to 
reduce cell proliferation in the PCa cell line DU145 but not in the more aggressive cell type, PC-3 
(Dhupkar et al., 2010).  One in vivo study of the use of Cetuximab plus doxorubicin in patients with 
CRPC showed no significant decline in PSA levels compared to the control group but an increase in 
OS (Slovin et al., 2009).  In addition, a randomised phase II trial of patients treated with Cetuximab 
plus mitoxantrone or Cetuximab plus mitoxantrone plus prednisone showed no significant 
improvement in OS or time to disease progression with the addition of Cetuximab (Fleming et al., 
2012).  Gefitinib inhibits EGFR tyrosine kinase by binding to the adenosine triphosphate (ATP)-
binding site of the enzyme thereby inhibiting the anti-apoptotic Ras signal transduction cascade 
(Bonaccorsi et al., 2004).  It has been shown in vitro to reduce invasion and proliferation of PC-3 and 
DU145 cells.  In phase II trials, however there was no improvement in disease load as measured by 
PSA levels (Small et al., 2007, Canil et al., 2005).  There is limited evidence for EGFR inhibitors as 
monotherapies.  This may be related to changes in expression of downstream kinases resulting in 
indirect drug resistance.  It is clear that growth factors play an important role in PCa progression but 
their efficacy as therapeutic targets for PCa is still to be fully elucidated. 
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2.6 Introduction to the intestinal cell kinase family and cancer 
Due to the lack of an effective therapeutic target for PCa, a number of high-throughput RNA-
interference based screens have been performed recently.  These studies identified novel proteins 
actively involved in the regulation of cell proliferation and survival of PCa cells.  One of these 
proteins was ICK.  It was identified by ours (unpublished observations) and other laboratories 
(Whitworth et al., 2012) to be a key protein essential for the growth of PCa cells.   
 
Intestinal cell kinase (ICK) (also known as MRK, MAK-related kinase), named after being cloned from 
the intestine, is a serine/threonine protein kinase ubiquitously expressed in most mouse, rat and 
human tissues (Fu, 2012).  Other members of the family include male germ cell-associated kinase 
(MAK) and MOK (MAPK/MAK/MRK-overlapping kinase).  Despite significant similarities in their N-
terminal catalytic domains, the family members diverge markedly in the sequence and structural 
organization of their C-terminal non-catalytic domains, which may confer distinct regulatory 
mechanisms and functional specificity.  A loss-of-function point mutation of ICK is the causative 
mutation in a neonatal lethal multiplex human syndrome endocrinecerebro-osteodysplasia, 
implicating a key role for ICK in the development of multiple organ systems (Lahiry et al., 2009).  
Furthermore, suppression of ICK expression in intestinal epithelial cells markedly impairs cell 
proliferation and G1 cell cycle progression (Fu et al., 2009).  There is a significant increase in the 
protein level of ICK in human primary colon cancer and ICK protein level is upregulated whereas 
MOK protein level is downregulated in mouse intestinal adenomas as compared with their adjacent 
normal intestinal mucosa (Chen et al., 2013). 
 
A second family member has been implicated in cancer development.  Male germ cell-associated 
kinase (MAK) was identified as an androgen-inducible co-activator of the androgen receptor in PCa 
cells (Ma et al., 2006).  Similar to the role of ICK in intestinal epithelial cells, MAK is also required for 
prostate epithelial cell replication (Ma et al., 2006).  MAK is over-expressed in PCa cells and in 
cultured cells.  Viral-mediated MAK overexpression results in mitotic defects such as centrosome 
amplification and lagging chromosomes via an androgen receptor -independent mechanism (Wang 
and Kung, 2012).  In vitro studies indicate that some protein components of the mitotic regulatory 
mechanism may be substrates for MAK and may thus play a role in PCa development. 
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2.7 Aims and objectives 
Prostate cancer is the most commonly diagnosed cancer in Australian men.  The overall objective of 
the laboratory program is to better understand the molecular mechanisms underlying the 
development of prostate cancer particularly the progression of the disease to advanced stages.  The 
overall aim of the current study was to focus on functions of intestinal cell kinase (ICK), as the 
protein was recently found to be upregulated in prostate tumours. 
The underlying hypothesis is that ICK has a central role in regulating prostate epithelial cell growth 
and that manipulation of ICK activity may influence growth and progression of prostate carcinoma 
cells. 
The specific aims of the project were: 
 to develop cellular tools for study of ICK mRNA and protein levels in tumour and non-tumour 
prostate cell lines 
 to determine the effect of manipulation of ICK expression on mRNA and protein levels of a 
potential downstream target(s) of ICK selected from a panel of candidates genes with 
functions associated with cancer cell growth 
 to conduct similar experiments with candidate genes with functions associated with cancer 
cell survival. 
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Chapter 3.0 Materials and methods 
3.1 Cell culture conditions 
The human PCa cell lines, PC-3, DU145, LNCaP, were obtained from the American Type Culture 
Collection (Manassa, USA).  C4-2 and C4-2B cells were kindly provided by Professor Leland Chung 
(Cedars-Sinai Medical Center, USA).  The immortalised non-tumorigenic prostate epithelial cell line, 
NPTX, was kindly provided by Professor Suzanne Topalian (National Cancer Institute, NIH, USA).  The 
prostate epithelial cells HPr-1 was established as described previously (Choo et al., 1999).  PC-3, 
DU145, LNCaP were maintained in RPMI 1640 growth medium (Life Technologies; catalogue 
number: 12633-012) supplemented with 5% (v/v) foetal bovine serum (FBS) (Life Technologies; 
catalogue number: 10099-141) and 2% (w/v) penicillin/streptomycin (P/S), (Life Technologies, 
catalogue number: 15070-063).  22Rv1 were grown in RPMI 1640 growth medium with 10% (v/v) FBS 
and 2% (v/v) P/S.  C4-2 and C4-2B cells were sustained in T-medium (Life Technologies; catalogue 
number: 0020056DJ) with 5% (v/v) FBS and 2% P/S (
w/v).  The non-tumorigenic prostate epithelial cell 
lines NPTX and HPr-1 were maintained in Keratinocyte-SFM (Life Technologies; catalogue number: 
17005-042) supplemented with human recombinant epidermal growth factor and bovine pituitary 
extract (Life Technologies; catalogue number: 3700-015) and 1% (w/v) P/S.  All cells were incubated 
at 37oC and 5% (v/v) CO2. 
 
3.2 Transfection 
3.2.1 Small interfering RNA  
To knockdown ICK expression in PCa cells, small interfering RNA (siRNA) specific for the ICK RNA 
were obtained from three different commercial companies (table 3.1).  The corresponding 
scrambled RNA oligo from each manufacturer was used as a negative control. 
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Sequence 
No. 
Manufacturer 
Catalogue 
No. 
Sense sequence Anti-sense sequence 
siRNA-1 Ambion S22514 GGACUCGCUUUAUUCACAtt UGUGAAUAAAUGCGAGUCCtt 
 
siRNA-2 Dharmacon L-004811-00-
005 
SMARTpool:ON-TARGET plus siRNA  
Pool of four sequences 
siRNA-3 Invitrogen 10620318 GGCACUUCGAUAUCCUUACUUCCAA UUGGAAGUAAGGAUAUCHAAHUHCC 
Table 3.1.  Short interfering RNA sequences for ICK knockdown. 
A total of 240,000 cells were seeded on a 6 well plate 24 hr before transfection.  Cells were 
transfected with siRNA using Lipofectamine RNAiMAX (Life Technologies; catalogue number: 13778-
075).  Five microlitres of RNAiMAX was mixed with 250 µL Opti-MEM® reduced serum medium (Life 
Technologies; catalogue number: 31985062) and left for 5 min at room temperature.  Meanwhile, 5 
l of 20 M of siRNA was diluted with 250 l Opti-MEM® and left for 5 min.  The two mixtures were 
combined and incubated for a further 20 min at room temperature.  Finally, the mixture was added 
dropwise into the cells and incubated for 6-12 hr.  Cells were collected 72, 96 or 120 hr post 
transfection. 
 3.2.1 ICK expression plasmid 
To overexpress ICK in PCa cells, a plasmid which encoded the full length human ICK protein tagged 
with green fluorescent protein (GFP) at the C-terminus region (pCMV6-ICK-GFP) was obtained from 
Origene (catalogue number: RG216454) (figure 3.1).   
 
Figure 3.1.  Map of pCMV6-ICK-GFP plasmid from Origene. 
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The plasmid was propagated in Escherichia coli as per the protocol outlined by PROMEGA (2014).  
Bacterial colonies were subsequently grown in ampicillin-resistant agar overnight at 37°C.  Colonies 
were transferred to a 40 mL tube containing Luria broth and ampicillin (100 µg/mL) and incubated 
for 18 hr at 37°C.  Five hundred microlitres of the culture was stored in 50% (v/v) glycerol stock at -
80°C.  The plasmid was purified using Spin MiniPrep Kit as per the manufacturer’s instructions 
(QIAGEN; catalogue number: 27104) and was then transfected into the C4-2B cells using X-
tremeGENE HP DNA transfection reagent (Roche; catalogue number: 06 366 236 001).  Eight 
microlitres of X-tremeGENE HP was mixed with 200 l of Opti-MEM® reduced serum medium, 2.5 g 
of plasmid and incubated for 15 min at room temperature.  The mixture was added dropwise into 
the well and incubated for at least 6 hr.  Cells were collected 72, 96 or 120 hr post transfection. 
 
3.3 Quantitative real-time polymerase chain reaction  
A cell pellet was collected following trypsinisation and the total RNA in each sample was purified 
using a QIAGEN RNeasy Mini Kit as per the manufacturer’s instructions (catalogue number: 74104).  
The total RNA concentration was measured using a spectrophotometer at 260 nm and 280 nm 
(Nanodrop, Thermoscientific).  The RNA purity was calculated using the 260:280 nm ratio and a ratio 
of ~2 was considered acceptable.  Between 0.5 and 2 µg of RNA was used to synthesize cDNA using 
the reagents and protocol provided by Life Technologies (catalogue number: 18080400).  
Quantitative PCR was performed by adding 5 µL of Syber Green (Life Technologies; catalogue 
number: 4472908), 0.1 µL of each reverse and forward primer specific for the genes of interest and 
internal control (60S ribosomal protein L32 table 3.2), 3.8 µL of RNAse free water and 1 µL of cDNA 
to a 384 well plate.  Each sample was repeated in triplicate and 3 non-template controls were run 
with each primer.  The fluorescence signal in each sample was measured using a Life Technologies 
ViiA 7 system as per manufacturer’s instructions (Life Technologies). 
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Primer Manufacturer Forward sequence Reverse sequence 
ICK Sigma Aldrich TTGCTTTTATGCCCTCTGAC GACCCTTCCCCTGGTTATTCC 
EGFR Sigma Aldrich CCGTCCAGTATTGATCGGGAG CCACCTCACAGTTATTGAACATCC 
p53 Sigma Aldrich GCGAATTCCAGTCTGAGTCAGG AAGGATCCAAGAGGAGCCGCAGT 
Rpl-32 Sigma Aldrich CCCCTTGTGAAGCCCAAGA GACTGGTGCCGGATGAACTT 
Table 3.2.  Primer sequences (5’ to 3’) and manufacturers. 
The fold change in mRNA was determined from the average threshold cycle number (Ct) for each set 
of samples.  The Ct number is the number of cycles at which the fluorescence signal in the samples 
exceeds the background signal.  The fold change in each gene was calculated using the Pfaffl 
equation:  (Pfaffl, 2001). 
 
3.5 Western blotting 
3.5.1 Protein lysate preparation 
Following trypsinisation, the insoluble protein pellet was collected and washed once with 1X 
phosphate buffered saline (PBS).  The insoluble protein pellet was incubated with 30- 60 µL 1X cell 
lysis buffer (CLB) containing 150 mM NaCl, 1.0% (w/v) Triton X-100, 50 mM Tris pH 8.0 and 1 mM 
phenylmethanesulfonylfluoride on ice for 20 min.  The insoluble protein was pelleted by 
microcentrifugation at 4°C for 20 min and the supernatant was recovered. 
3.5.2 Measurement of total protein concentration 
A standard curve was created by diluting a 2 mg/mL solution of bovine serum albumin 
(Thermoscientific; catalogue number: 23209) to 9 concentrations (2000, 1500, 1000, 750, 500, 250, 
125, 25, 0 µg/mL) with CLB.  The total protein concentration was calculated using a Bicinchoninic 
acid (BCA) protein assay kit supplied by Thermoscientific (catalogue number: 23227).  The BCA 
reagent was prepared as per the manufacturer’s instructions and 2 μl of protein sample was added 
to 200 µL of reagent.  The solution was incubated at 37°C for 30 min and the light intensity at 562 
nm was measured with the FLUOstar Omega microplate reader (Isogen Life Science B.V).  The total 
protein in each sample was determined based on the standard curve. 
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3.5.3 SDS-PAGE gel electrophoresis and protein transfer 
All samples were adjusted to the same concentration, typically between 10 and 30 µg.  Each sample 
was diluted to the same total volume (9 µL).  Two microliters of 6X sample buffer containing 350 mM 
Tris-HCL (pH 6.8), 30% (v/v) glycerol, 21.4% (
v/v) mercaptoethanol, 10% (
w/v) SDS and 0.01% (
v/v) 
bromophenol blue was added to each sample and the mixture was incubated at 100oC for 8 min.  
Equal concentrations of sample were loaded onto the SDS-PAGE gel with either 10% (w/v) or 12.5% 
(w/v) acrylamide.  Five microliters of the Rainbow molecular weight marker (GE Healthcare; catalogue 
number: RPN 800E) was also loaded.  The gel was run at 100 V for 60 min in running buffer 
containing 25 mM Tris-HCl, 192 mM glycine and 0.1% (w/v) SDS.  Following gel electrophoresis, the 
proteins on the gel were transferred to a PVDF membrane at 100 V for 75 min in transfer buffer 
containing 25 mM Tris-HCl, 192 mM glycine and 20% (v/v) methanol. 
3.5.4 Blocking and blotting of the membrane. 
The membrane was blocked with 5% (w/v) non-fat milk in Tris-buffered saline-Tween 20 (TBST, 20 
mM Tris-HCl, 137 mM NaCl, 0.1% (w/v) Tween 20) for 60 min.  The membrane was washed three 
times for 5 min each and was incubated with the primary antibody (table 3.3) in 5% (w/v) non-fat milk 
overnight at 4°C.  The membrane was washed for 5 min three times with TBST and incubated with 
the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody (table 3.3) in 5% (w/v) 
non-fat milk for 60 min at room temperature.  The membrane was washed 3 times for 5 min. 
 
Antibody Species Dilution 
Catalogue 
number 
Manufacturer 
Estimated size 
(kDa) 
ICK  Rabbit 1:250 H00022858-D01P Abnova Corporation 72 
ICK Goat 1:250 sc-48020 Santa Cruz biotechnology 72 
ICK  Mouse 1:250 sc-365244 Santa Cruz biotechnology 72 
ICK  Rabbit 1:250 PA001113 Sigma-Aldrich 72 
Actin  Goat 1:1000 sc-1616 Santa Cruz biotechnology 44 
Phospho-
p38  
Rabbit 1:1000 4511S Cell Signalling 38 
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Phospho-
FAK  
Rabbit 1:1000 3281S Cell Signalling 125 
PRK2  Rabbit 1:1000 2612S Cell Signalling 140 
Phospho-
Jak-2  
Rabbit 1:1000 3771S Cell Signalling 125 
ID1  Rabbit 1:500 Sc-488 Santa Cruz biotechnology 16 
phospho-
Fox01  
Rabbit 1:1000 9461S Cell Signalling 82 
Cyclin-B1  Mouse 1:500 Sc-7393 Santa Cruz biotechnology 55 
phospho-c-
jun  
Rabbit 1:1000 3270 Cell signalling 48 
p16  Mouse 1:1000 5A8A4 Thermoscientific 16 
ARK-1  Rabbit 1:500 sc-25425 Santa Cruz biotechnology 45 
EGFR  Rabbit 1:500 Sc-03 Santa Cruz biotechnology 170 
p53  Mouse 1:1000 M7001 Dako 53 
p21  Mouse 1:500 M7202 Dako 21 
Cleaved 
PARP  
Rabbit 1:1000 9541 Cell signalling 89 
Ƴ-tubulin  Rabbit 1:1000 T5192 Sigma-Aldrich 48 
IgG HRP 
conjugated 
Rabbit 1:5000 NA934V GE Healthcare  
IgG HRP 
conjugated 
Mouse 1:10000 NA931V GE Healthcare  
IgG HRP 
conjugated 
Goat 1:5000 Sc-2020 Santa Cruz biotechnology  
Table 3.3.  Primary and secondary antibodies used in study. 
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3.5.4 Signal detection 
Positive signal was visualised by enhanced chemiluminescence (ECL) using a HRP substrate from 
Merck-Millipore (catalogue number: WBKLS0500).  The signal intensity was measured on a 
ChemiDoc MP system from Biorad using ImageLab 4.0.1 data analysis software (Biorad). 
 
3.6 Immunofluorescence staining 
5.0 x104 cells were seeded on a sterile coverslip inside a 24 well plate.   Cells were transfected with 
scrambled control or siRNA-1.  Forty eight hours post transfection, the cells were washed twice with 
PBS, fixed with 4% (v/v) formaldehyde in PBS for 10 min and washed another three times with PBS.  
The cells were permeabilized with 0.25% (v/v) Triton X-100 in PBS for 15 min and blocked for 60 min 
in 2% (w/v) BSA.  The cells were incubated with the Sigma ICK antibody (1:250) for 120 min at room 
temperature.  The cells were washed three times with PBS for 10 min and incubated with Alexa 
Fluor® 488 secondary antibody (Abcam; catalogue number: ab150077) for 30 min prior to washing 
with PBS.  Counterstaining of the nuclei was performed with 4’,6-diamidino-2-phenylindole (DAPI) 
(Life Technologies; catalogue number: D3571) and the cells were washed with PBS.  The coverslip 
was mounted on a slide with mounting medium and left to dry overnight before being visualised 
with a Nikon E600 fluorescence microscope (Rhodes) at wavelength 488 nm for ICK and for 358 nm 
for DAPI. 
 
3.7 Luciferase reporter assay 
Luciferase reporter assay was performed with the pER-1 plasmid (luciferase reporter containing the 
EGF-R promoter, kindly donated by Dr A. Johnson, NCI, MD, USA) and pRL-TK-Luc (internal control).  
0.25 µg of these two plasmids were co-transfected with either the 0.25 µg of pCMV6-GFP or pCMV6-
ICK-GFP plasmid.  The DNA was mixed with 1 µL of Lipofectamine™ 2000 reagent (Life Technologies; 
catalogue number: 11668-027) in 50 µL of Opti-MEM® reduced serum medium as per the 
manufacturer’s instructions.  Luciferase activity was determined with the Dual Luciferase reporter 
assay kit (Promega; catalogue number: TM040). Luminescent signal was quantitated with the 
FLUOstar Omega microplate reader (Isogen Life Science B.V) and was normalized with the internal 
control (Renilla). 
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3.8 Flow cytometry 
3.8.1 Annexin V staining 
Apoptotic cells were examined by the Annexin V staining kit (BD Pharmingen; catalogue number: 
550474) as per the protocol provided by the manufacturer.  After staining, cells were analysed with a 
BD LSR II flow cytometer (San Jose, USA) based on the intensity of fluoresescein isothiocynate and 
propidium iodide staining.  Data was analysed using FlowJo data analysis software (Oregon, USA). 
3.8.2 Cell cycle analysis 
Cells were fixed with 1 mL of cold 70% (v/v) ethanol and stored at 4
oC for 24 hr.  After fixation, cell 
pellets were collected by centrifugation, resuspended in 500 μl of PBS and incubated at 4oC for 24 hr 
prior to performing flow cytometry analysis.  The cells were stained with 15 µL of propidium iodide 
(1 mg/ml) and 25 µL of RNase (1 mg/ml) for 30 min.  Cell cycle analysis was performed with a BD LSR 
II flow cytometer (BD Biosciences) and analyzed using FlowJo data analysis software. 
3.9 Statistical analysis 
Statistical analysis was performed using Microsoft Excel software.  For most of the qRT-PCR 
experiments and the luciferase reporter assay, the experiment was repeated at least three times 
with samples collected from separate experiments.  The fold change was determined for each 
sample, for each experiment and the mean and standard deviation was calculated from the three 
replicate experiments.  For Western blot analysis, the relative protein expression was normalized 
with that of the control sample using the ImageLab software and the mean and standard deviation 
was calculated from three replicate experiments.  A Students T-test was used to determine 
significance and a P value of <0.05 was considered significant. 
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Chapter 4.0  Intestinal cell kinase regulates epidermal growth factor receptor 
expression in prostate cancer cells 
4.1 Introduction 
As described earlier, the search for novel therapeutic targets for prostate cancer has identified the 
protein, intestinal cell kinase (ICK) as potential regulator of growth in prostate cancer cells (Haggarth 
et al., 2011).  The function of ICK is still largely unclear.  Activation of ICK has been shown to occur by 
phosphorylation of a threonine-aspartate-tyrosine motif in the activation loop.  In contrast to the 
mitogen activated protein kinases (MAPKs), which are activated by growth factors, the upstream 
activating kinase for ICK is cell cycle related kinase (CCRK).  Deactivation is via protein phosphatase 5 
(PP5) and thus with CCRK, the pair of proteins act as yin-yang regulators of ICK activity (Fu et al., 
2006) (figure 4.1).  Recently, CCRK was shown to be downstream of mammalian Sonic hedgehog 
signal transduction (Ko et al., 2010) and may thus play important roles in many cellular functions.  
CCRK is a suppressor of apoptosis (MacKeigan et al., 2005) and is known to be important for cell 
growth (Wohlbold et al., 2006).  It is a novel candidate oncogene in hepatocellular carcinoma (Feng 
et al., 2011).  PP5 plays an important role in the cellular response to DNA damage and in control of 
cell division (Golden et al., 2008) by regulating cell cycle progression at the p53-dependent G1 
checkpoint (Zuo et al., 1998).  Identification of ICK as a downstream target of CCRK and/or PP5 
supports a role of ICK in the regulation of proliferation and/or apoptosis and in modulating some 
branch of checkpoint signalling in response to stress and DNA damage. 
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Figure 4.1.  The activation and downstream targets of ICK. 
Activators are shown in green and deactivators in red. 
Recently, proteins such as Scythe and Raptor have been identified as direct ICK substrates.  
Phosphorylation of Scythe has been shown to regulate cell survival in bone tumour cells (Yong and 
Wang, 2012).  On the other hand, phosphorylation of Raptor is essential in activation of the 
mammalian target of rapamycin (mTOR), which is involved in the regulation of normal and cancer 
cell growth  (Laplante and Sabatini, 2009).  mTORC1 stimulates cell growth and proliferation by 
phosphorylation of two key regulators of mRNA translation and ribosome biogenesis, ribosomal 
protein S6 kinase 1 and eukaryotic initiation factor 4E-binding protein 1 (Ma and Blenis, 2009).  In 
addition cyclin D1 and c-Myc are specific downstream targets of activated mTORC1 (Fu et al., 2009).  
Nevertheless, it is still unclear whether ICK regulates cell proliferation and cell cycle progression 
through activation of the mTORC1 signalling pathway (Wu et al., 2012). 
 
To better understand how ICK regulates PCa cell proliferation, in this study ICK was either reduced or 
overexpressed in PCa cells.  Examination of a series of proteins associated with cell proliferation 
revealed that ICK regulates EGFR, a growth factor receptor that regulates cell proliferation and cell 
cycle progression.  In PCa cells, knockdown of ICK resulted in downregulation of EGFR protein, while 
overexpression of ICK induced EGFR protein expression.  Both EGFR promoter activities and mRNA 
expression were upregulated by ICK, suggesting that ICK regulates EGFR expression through 
35 
 
induction of gene transcription.  Consistent with these findings, overexpression of ICK in a non-
tumorigenic prostate epithelial cell line not only induced cell cycle progression, but also upregulated 
EGFR protein.  These data confirm that EGFR functions as a novel ICK downstream target in PCa cells.   
 
4.2 Results 
4.2.1 ICK expression in prostate cancer cell lines 
4.2.1.1 Examination of ICK mRNA level by quantitative real time- polymerase chain reaction 
(qRT-PCR) 
To understand the function of ICK in PCa cells, the levels of ICK mRNA were examined in a panel of 
prostate cell lines (table 4.1) with qRT-PCR.  Two non-tumorigenic human prostate epithelial cell 
lines, NPTX and HPr-1 and six human PCa cell lines, PC-3, DU145, LNCaP, C4-2, C4-2B and 22Rv1 were 
grown in their corresponding growth media before being lysed for RNA extraction (table 4.1).  
Examination of ICK mRNA level with a pair of ICK specific primers revealed that ICK mRNA was highly 
upregulated in all of the PCa cell lines when compared to the non-tumorigenic prostate epithelial 
cells (figure 4.2).  However, the level of ICK did not appear to correlate with the aggressiveness of 
the cancer cell lines, since its level in the most aggressive cell line (i.e.  PC-3) was indeed lower than 
the less aggressive cell line 22Rv1.   
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 Cell Line Description 
 
Non-tumorigenic 
NPTX  Immortalized normal prostate epithelial 
HPr-1  Immortalized normal prostate epithelial 
 
 
 
 
Tumorigenic 
PC-3 
 High tumorigenicity 
 Bone derived 
 Androgen unresponsive 
DU145 
 Moderate tumorigenicity 
 Brain derived 
 Androgen unresponsive  
LNCaP 
 Very low tumorigenicity 
 Lymph node derived 
 Androgen responsive 
C4-2 
 Moderate tumorigenicity 
 Derived from LNCap cells 
 Androgen resistant 
C4-2B 
 High tumorigenicity 
 Derived from C42 cells 
 Androgen resistant 
22RV1 
 Moderate tumorigenicity 
 Human carcinoma xenograft derived 
 Mildly androgen dependent 
Table 4.1.  Summary of the cell lines used in this study. 
 
 
Figure 4.2.  qRT-PCR of ICK expression in different cell lines. 
mRNA isolated from the different cell lines was examined by qRT-PCR with the ICK primers and the results are presented as 
fold change (mean ± SD) relative to the value of NPTX cells for triplicate samples from a single experiment. 
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4.2.1.2 Detection of endogenous ICK by Western blot analysis 
Next, ICK protein level in PCa cells was determined using Western blot analysis.  To optimize the 
conditions for Western blot analysis, four commercially available antibodies were tested against 
protein lysates of DU145 and PC-3 cells.   
As shown in Figure 4.3, the antibodies from Abnova and Santa Cruz failed to generate a specific 
signal corresponding to the ICK protein in both DU145 and PC-3 cells.  Other researchers noted that 
the intensity of the band detected by the Santa Cruz monoclonal antibody varied between 
experiments unrelated to those reported here.  Consequently, it was deduced that the antibody was 
not detecting endogenous ICK but was binding another protein with a similar size.  On the other 
hand, the antibody from Sigma produced a band in DU145 and PC-3 cell lysates with size similar to 
that of ICK.  This antibody was therefore chosen for subsequent analysis of ICK expression in all the 
cell lines.   
 
 
Figure 4.3.  Western blot analysis of endogenous ICK protein in PCa cells using various anti-ICK antibodies. 
20 micograms of total cell lysate from DU145 and PC-3 cells was examined with Western blotting using four different anti-
ICK antibodies and actin (loading control).  The same membrane was stripped of antibody and probed with the Adnova and 
Santa Cruz antibodies and the same actin image was used as a loading control for each antibody.  A separate set of cell 
lysates was used for the Sigma antibody.  This image was spliced together to remove empty lanes. 
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Next, the levels of ICK protein were determined in the same panel of prostate cell lines described 
earlier (figure 4.4).  Although ICK protein could be detected in all cell lines, the level was higher in 
the PCa cell lines when compared to the non-tumorigenic prostate epithelial cells.  This appeared to 
correlate with the result from the qRT-PCR analysis (figure 4.2).  ƴ-tubulin was used as a loading 
control, as endogenous expression remains relatively consistent across different cell lines.   
 
Figure 4.4.  Western blot analysis of ICK protein expression in different PCa cell lines. 
Fifteen micorgrams of total cell lysate from all cell lines was examined with Western blot analysis against ICK and ƴ-tubulin 
(loading control) antibodies.  The image was spliced together to remove empty lanes. 
 
4.2.1.3 Subcellular localisation of ICK in prostate cancer cells. 
To investigate the localisation of ICK protein within the PCa cells, immunofluorescence staining was 
performed with the ICK antibody.  Although high levels of ICK were detected in the cytoplasm, ICK 
was also found in the cell nuclei as indicated by the colocalization of the signal with the DAPI staining 
(figure 4.5).  These observations concur with previously published data by Fu et al. (2005), which 
showed GFP-conjugated ICK to be expressed in both the cytoplasm and nucleus of human embryonic 
kidney cells. 
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Figure 4.5.  Immunofluorescence staining of C4-2B cells with DAPI and ICK antibody (40x magnification) 
C4-2B cells were prepared as per the protocol outlined in chapter 3.6.  Following incubation with primary and secondary 
antibodies cells were counterstained with DAPI.  (A)  DAPI staining in blue.  (B) ICK staining is shown in red.  (C) Overlay 
staining in purple.  Open arrow indicates nucleus, closed arrow indicates cytoplasm (Scale bar = 100 µm). 
 
4.2.1.4 Knockdown of ICK expression in prostate cancer cells by ICK specific siRNA. 
To determine the function and the downstream targets of ICK in PCa cells, siRNA-mediated gene 
knockdown was performed to suppress the endogenous expression of ICK.  Three different ICK-
specific siRNAs (siRNA 1-3) that target different sequences of the ICK mRNA were trialled in PC-3 
cells.  Transfection of each of the three siRNAs resulted in a marked downregulation of the level of 
ICK mRNA when compared to cells transfected with the scrambled control 72 (figure 4.6).  siRNA-1 
was chosen for further validation with C4-2B cells and for subsequent experiments involving 
knockdown of ICK (figure 4.6). 
 
To confirm that the knockdown of ICK mRNA by siRNA transfection led to suppression of ICK protein, 
total cellular protein was collected from PC-3 cells transfected with either the scrambled control or 
siRNA-1 and analysed with Western blots against ICK antibody.  Knockdown of ICK with siRNA-1 
resulted in almost complete reduction of the ICK protein in PC-3 cells (figure 4.7).  Similarly, 
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transfection of C4-2B with the same siRNA also resulted in a reduction of ICK protein, suggesting that 
the siRNA approach can effectively suppress endogenous ICK expression in PCa cells (figure 4.7). 
 
Figure 4.6.  qRT-PCR analysis of ICK mRNA following knockdown with siRNA-1, -2 and -3 in PC-3 cells and 
siRNA-1 in C4-2B cells. 
(A-C) Changes in ICK mRNA level in PC-3 cells 72 hours following ICK knockdown with siRNA-1, 2 and 3 in PC-3 cells.  Data 
represents mean + SD or triplicate samples from a single experiment.  (D) Further validation of the effect of siRNA-1 on ICK 
expression in C4-2B cells 72 hours post transfection.  (D) data represents mean + SD from three replicates. 
 
 
Figure 4.7.  Western blot analysis of ICK following knockdown with siRNA-1 in PC-3 and C4-2B cells. 
Cells transfected with either scrambled control or siRNA-1 were lysed 72 hours post transfection.  Twenty microlitres of 
total cell lysate was examined with Western blot analysis against ICK and actin (loading control) antibodies. 
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4.2.2 Identification of EGFR as a novel downstream target of ICK. 
Since ICK is known to regulate cell cycle progression, in order to delineate its downstream signalling 
pathway, the effect of ICK knockdown on the expression of a selection of proteins involved in the 
regulation of cell cycle progression and cell proliferation of cancer cells was first investigated using 
Western blotting (table 4.2).  As the 22Rv1 cell line expressed the highest level of ICK protein (figure 
4.4), it was used initially for the knockdown experiments.  Unfortunately, all experiments with 22Rv1 
cell line were discontinued when the cells were found to be contaminated with xenotropic murine 
leukaemia virus-related virus.  The C4-2B cell line, which also expressed high levels of ICK, was thus 
chosen as it attached easily to plates/flasks and has a high proliferation rate. 
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CELL PROLIFERATION-RELATED PROTEINS 
Protein Characteristics 
p16 
 p16 inhibits the activity of cyclin-dependent kinase complexes necessary for 
transition through the G1 phase of the cell cycle (Plath et al., 2000) 
 Loss of p16 expression common in metastatic cancers (Jarrard et al., 2002) 
Phosphorylated-  
Janus kinase-2 
(Jak-2) 
 tyrosine kinase  
 involved in cell proliferation (Frenzel et al., 2006) 
 involved in the autocrine signal transduction of the growth factor, prolactin 
in metastatic and CRPC (Dagvadorj et al., 2007) 
Inhibitor of DNA-
binding 1 (ID1) 
 transcription factor that induces DNA synthesis (Maw et al., 2009) 
 Increased expression associated with increasing PCa tumour grade (Sharma 
et al., 2012) 
phosphorylated 
Forkhead box O1 
(FOXO1) 
 transcription factor 
 important in balancing cell growth and cell cycle arrest in response to stimuli 
 phosphorylated protein translocates from the nucleus to the cytoplasm 
where it is degraded (Glauser and Schlegel, 2007) 
 deregulated expression promotes the development of CRPC (Zhao et al., 
2014)  
Cyclin B1 
 key initiator of mitosis (Jackman et al., 2003) 
 expression of the cyclin B family of proteins increase throughout cancer 
progression (Maddison et al., 2004) 
Aurora related kinase-
1 (ARK-1) 
 kinase critical for cell cycle control (Fu et al., 2007) 
 overexpression can result in errors in spindle formation, chromosome 
segregation errors and errors in cytokinesis 
Epidermal growth 
factor receptor (EGFR) 
 a cell surface receptor 
 activated by extracellular ligands such as EGF 
 initiates MAPK signalling cascade and PI3K pathway (Dhillon et al., 2007) 
 EGFR-MAPK signalling pathway is involved in cell proliferation 
 aberrant activation present in many cancers 
 EGFR overexpression in ~50% of cancers (Roberts and Der, 2007) 
Table 4.2.  Summary of cell proliferation proteins and their functions. 
 
Examination of each protein in the above table using Western blotting revealed that expression of 
most of the proteins (Jak-2, ID1, cyclin B1 and ARK-1) remained unchanged following ICK knockdown 
in C4-2B cells (figure 4.8A).  A slight change in the level of p16 and FOXO1 expression was observed.  
Most importantly, the protein expression of EGFR, a key regulator of cell proliferation which is 
frequently overexpressed in PCa, was found to be downregulated significantly following ICK 
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knockdown, suggesting that EGFR may function as the main downstream target of ICK in PCa cells 
(figure 4.8 B). 
 
  
 
Figure 4.8.  Western blot analysis of cell proliferation-related proteins in C4-2B cells following ICK 
knockdown.  
(A) C4-2B cells were transfected with either scrambled control or siRNA-1 then lysed 72 hr later.  Twenty microlitres of 
total cell lysate was analysed with Western blotting using antibodies against ICK, phospho-Jak-2, ID1, phospho-Fox01, 
cyclin-B1, EGFR and actin (loading control).  (B) Graph represents mean + SD from 3 replicate measurements of EGFR 
protein following ICK knockdown. *P<0.05 Student’s t-test. 
 
4.2.2.1 ICK regulates EGFR mRNA expression. 
To investigate if the decrease in EGFR protein level after ICK knockdown is mediated through 
regulation of EGFR mRNA levels, C4-2B cells were transfected with either scrambled control or 
siRNA-1.  Changes in EGFR mRNA expression were then determined using qRT-PCR.  Knockdown of 
ICK resulted in downregulation of EGFR mRNA level in C4-2B cells (figure 4.10).  Similar results were 
observed in C4-2B cells that were transfected with a second ICK siRNA targeting another mRNA 
sequence (data not displayed), further supporting the conclusion that ICK regulates EGFR protein 
expression through modulation of the EGFR mRNA level. 
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Figure 4.9.  qRT-PCR analysis of EGFR mRNA expression in C4-2B cells following ICK knockdown. 
Changes in EGFR mRNA level in C4-2B cells 72 hr following transfection with scramble or siRNA-1.  Data represents mean + 
SD from 3 replicate experiments. *P<0.05 Student’s t-test. 
 
4.2.2.2 Overexpression of ICK in PCa cells induces EGFR expression. 
In order to confirm the above findings, C4-2B cells were transfected with a construct that expresses 
a GFP-tagged ICK protein.  Ectopic expression of ICK mRNA and protein expression was then 
confirmed with both qRT-PCR and Western blot analyses (figure 4.10).  Examination of the EGFR 
mRNA with qRT-PCR indicated that ICK overexpression resulted in increased levels of EGFR mRNA 
(figure 4.11).  Consistent with the changes in mRNA, there was also a significant induction in EGFR 
protein expression (figure 4.12) in ICK overexpressing cells.  These findings provide solid support that 
ICK regulates EGFR protein level through modulation of EGFR mRNA expression. 
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Figure 4.10.  qRT-PCR and Western blot analysis of ICK mRNA and protein expression following transfection 
of C4-2B cells with an ICK overexpression vector. 
(A) Changes in ICK mRNA level in C4-2B cells 72 hr following transfection with pCMV6-GFP or pCMV6-ICK-GFP.  Data 
represents mean + SD from 3 replicate experiments.  (B) Protein level was analysed with Western blot analysis against ICK 
and actin (loading control) in 20 µL of total cell lysate.   
 
 
 
Figure 4.11.  qRT-PCR analysis of EGFR mRNA following ICK overexpression in C4-2B cells. 
Changes in EGFR mRNA level in C4-2B cells 72 hr following transfection with pCMV6-GFP or pCMV6-ICK-GFP.  Data 
represents mean + SD from 3 replicate experiments. *P<0.05 Student’s t-test. 
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Figure 4.12.  Western blot analysis of EGFR following ICK overexpression in C4-2B cells. 
C4-2B cells were transfected with either pCMV6-GFP or pCMV6-ICK-GFP, lysed 72 hr later.  Twenty microlitres of total cell 
lysate was analysed with Western blotting against ICK, EGFR and actin (loading control).  Graph represents mean + SD from 
3 replicate experiments.  *P<0.05 Student’s t-test. 
 
To investigate whether ICK induced EGFR mRNA through upregulation of EGFR gene transcription, a 
luciferase reporter assay was performed.  This was done by transfecting C4-2B cells with an ICK 
expression construct and a construct that expresses the luciferase reporter gene driven by the EGFR 
promoter.  The effect of ICK on the EGFR-promoter activities was then determined by measuring the 
luciferase activity with a luminometer.  In cells overexpressing ICK, a higher level of luciferase activity 
was observed, indicating that ICK upregulates EGFR gene transcription through induction of the 
EGFR-promoter (figure 4.13).   
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Figure 4.13.  Luciferase reporter activity in control and ICK overexpressed C4-2B cells. 
C4-2B cells were co-transfected with a bioluminescent reporter gene driven by the promoter region of EGFR and either 
pCMV6-GFP or pCMV6-ICK-GFP.  The cells were collected 48 hr post transfection.  The total protein was collected and the 
absorbance measured using a luminometer.  Each sample was adjusted for an internal standard.  Data represents mean 
absorbance + SD from 3 replicate experiments. *P<0.05 Student’s t-test. 
 
In order to confirm that ICK also regulated EGFR in non-tumorigenic prostate epithelial cells, 
Western blot analysis was performed to examine EGFR protein level in HPr-1 cells stably transfected 
with either empty vector control or vector expressing ICK.  As shown in figure 4.14, a significant 
induction of EGFR was observed in the ICK overexpressing cells. 
 
To further investigate whether the induction of EGFR by ICK in non-tumorigenic cells was associated 
with an increase in cell proliferation, cell cycle analysis was performed on the control and ICK 
overexpressed stable HPr-1 cell lines (figure 4.15).  Consistent with an increase in cell cycle 
progression, a lower percentage of cells in G1 phase was observed in the ICK overexpressing cells 
when compared to the control cells.  Moreover, the percentage of cells in G2M phase was higher in 
the ICK overexpressed cells relative to the control.   
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Figure 4.14.  Western blot analysis of EGFR following in ICK overexpressing HPr-1 cells. 
Cells were transfected with either control or over expression vector.  Fifteen microlitres of total cell lysate was analysed 
with Western blot analysis against ICK, EGFR and actin (loading control).  Graph represents mean + SD from 3 replicate 
experiments.  *P<0.05 Student’s t-test. 
 
 
Figure 4.15.  Cell cycle analysis of HPr-1 cells overexpressing ICK. 
Empty vector and ICK overexpressed cell lines were seeded and collected after 48 hours.  Cells were prepared for analysis 
as outlined in chapter 2 and measured using LSR II flow cytometer.  This experiment was repeated in duplicate. 
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4.3 Discussion 
Although ICK is known to regulate cell proliferation in normal and cancer cells, the underlying 
mechanism is still largely unknown.  In this study, EGFR was identified and validated as a novel 
downstream target regulated by ICK in PCa cells. 
ICK mRNA has previously been shown to be upregulated in breast, colon and lung cancer cell lines 
(Sturgill et al., 2010).  In this study, ICK mRNA and protein levels were also found to be higher in 
cancer cells relative to non-tumorigenic cells.  Interestingly, ICK mRNA levels in the LNCaP cells were 
lower than the castration resistant PCa cell lines (C4-2 and C4-2B cells).  In a previous study, ICK 
transcription was found to be activated by FOXA1, a transcription factor which promotes aberrant 
androgen receptor activation in castration resistant PCa cells (Sturgill et al., 2010).  This may indeed 
explain the increase in ICK mRNA in the castration resistant line.  Surprisingly, however, the protein 
level of ICK was found to be higher in LNCaP cells among the three cell lines.  Therefore, it remains to 
be elucidated whether ICK may play any role in the development of the castration resistant 
phenotype of the PCa cells.   
While the exact function of ICK in cancer is not clear, ICK appears to play an essential role in the 
normal development of multiple tissues, as evidenced by the developmental disorder, endocrine-
cerebro-osteodysplasia, associated with a mutation in the ICK gene (Chen et al., 2013).  Examination 
of the gene expression profile of the skin fibroblasts from the affected patients revealed that the 
main signalling pathway associated with the condition is the JAK-STAT cascade (Dutta and Li, 2001).  
JAK-STAT signalling has been shown to regulate both cell proliferation and invasion (Dutta and Li, 
2001)  Aberrant activation of JAK-STAT has been reported in a number of cancers (Tam et al., 2007).  
However, in PCa cells, the phosphorylation level of JAK2, which regulates its activation, was not 
affected by knockdown of ICK.  Consistently, knockdown of ICK also failed to affect expression of ID1, 
a protein known to be regulated by JAK2 (Tam et al., 2008).  Thus, it is possible that the association 
between ICK and JAK-STAT activities could be tissue specific, although further examination is needed 
to confirm this hypothesis. 
Considering the reported role of ICK in the regulation of cell cycle progression, it is somewhat 
surprising that the level of many of the cell cycle regulators such as cyclin B1 and ARK-1 remain 
unchanged after ICK knockdown.  However, a significant decrease in EGFR mRNA and protein levels 
was observed in cells with knockdown of ICK.  In both non-tumorigenic prostate epithelial cells and 
PCa cells, ectopic ICK expression has been shown to upregulate EGFR expression.  Although we were 
unable to show the effect of ICK knockdown on EGFR promoter activities due to the fact that there 
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was an increase in apoptosis (as discussed in chapter 5), overexpression of ICK was found to 
significantly induce EGFR promoter activation.  Therefore, ICK appears to induce EGFR expression 
through regulation of its promoter activities, although the exact mechanism is unclear.  Since ICK has 
not been shown to bind to DNA, it is likely to act through an indirect mechanism rather than directly 
regulating the EGFR promoter.   
Due to its pivotal role in maintaining cell growth and survival of both normal and cancer cells, EGFR 
has long been established as a key anti-cancer target.  EGFR activates a long list of signalling 
pathways, which include the mTOR cascade.  Interestingly, one of the proteins known to be 
phosphorylated by ICK is Raptor.  Raptor is known to activate the mTOR signalling pathway, leading 
to subsequent induction of downstream targets essential for cell growth and survival (Davis et al., 
2014).  Our finding that ICK significantly upregulated EGFR mRNA and protein levels suggests that 
ICK may regulate mTOR activation through both direct and indirect mechanisms, and that 
inactivation of ICK may have dual inhibitory effect on mTOR activation.   
Taken together, these findings suggest that ICK plays a key role in regulating the mRNA and protein 
level of EGFR in both non-tumorigenic prostate epithelial cells and PCa cells, possibly through 
regulation of the EGFR promoter activity.   
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Chapter 5.0 ICK regulates prostate cancer cell survival 
5.1 Introduction 
Apoptosis, also known as programmed cell death, is a process essential for eliminating tumour cells 
within the normal organs.  Chemotherapeutic compounds, such as cabazitaxel and docetaxel, work 
by inducing cellular apoptosis either through induction of mitotic arrest or by inhibiting 
antiapoptotic proteins (Fitzpatrick and de Wit, 2014).  Similar to other cancers, PCa cells are capable 
of evading apoptosis by modulating the expression of pro-apoptotic factors  (Fernald and Kurokawa, 
2013), leading to treatment failure and disease progression.  The p53 and p38 signalling cascades are 
among the most studied pro-apoptotic pathways, are frequently inactivated in cancer, and may be 
involved in treatment sensitivity of PCa cells (Barbieri et al., 2013). 
Although ICK has been found to regulate proteins (for example, Scythe and c-Myc) known to be 
important in cellular apoptosis, it has not been reported to regulate cell survival.  In this study, it was 
determined that ICK expression is crucial for the survival of PCa cells.  Knockdown of ICK in PCa cells 
not only increased Annexin V positive population, but also induced the cleavage of PARP, suggesting 
that ICK is involved in suppressing cellular apoptosis.  Moreover, ICK knockdown was found to 
upregulate both p53 and p21 protein expression, while ectopic ICK expression was found to suppress 
both proteins.  Therefore, the findings revealed for the first time that ICK regulates PCa cell survival, 
possibly through suppression of the p53/p21 signalling pathway.  
 
5.2 Results 
 
5.2.1  Loss of ICK induces apoptosis 
 
To determine if ICK regulates PCa cell survival, C4-2B cells were transfected with either the 
scrambled control or siRNA-1.  Examination of cell morphology under phase contrast microscope 
revealed that there was an increase in detached cells 72 hr after transfection with the siRNA-1 
(figure 5.1).  To determine if the increase in detached cells was the result of induction of cellular 
apoptosis, Annexin V staining was performed to quantify the apoptotic population in C4-2B cells 
after knockdown of ICK.  While approximately 60% of the C4-2B cells transfected with scrambled 
control were viable 96 hr after transfection, a significant increase in early (quadrant 4) and late 
apoptosis (quadrant 2) was evident in cells transfected with siRNA-1 (figure 5.2).  Similarly, an 
increase in apoptosis was also observed at 120 hr after transfection with siRNA-1 (figure 5.3).  To 
further confirm the results, the level of PARP cleavage (Cl-PARP), a commonly used marker for 
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assaying cellular apoptosis, was determined in cells collected at 72, 96 and 120 hr post transfection.  
An increase in Cl-PARP was observed in the ICK knockdown cells at each time point relative to the 
control.  The level of Cl-PARP appeared to be higher at 120 hr than 72 hr (figure 5.4).   
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Figure 5.1.  Phase contrast images of C4-2B cells transfected with scramble or siRNA-1 (10x magnification). 
C4-2B cells were photographed at 72, 96 and 120 hr post transfection with a phase contrast microscope.  (A) Scrambled 
control cells at 72 hr.  (B) siRNA-1 cells at 72 hr.  (C) Scrambled control cells at 96 hr.  (D) siRNA-1 cells at 96 hr.  (E) 
Scrambled control cells at 120 hr.  (F) siRNA-1 cells at 120 hr.  Arrow indicates detached cells.  Scale bar = 100µm 
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Figure 5.2.  Annexin V staining of C4-2B cells 96 hr post ICK knockdown. 
C4-2B cells were stained with Annexin V 96 hr post transfection with scrambled control or siRNA-1.  (A) Representative 
FACS analysis of the Annexin V positive population at 96 hr.  (B) Graph represents mean + SD from 3 replicate experiments 
for viable cells.  *P<0.05 Student’s t-test. 
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Figure 5.3.  Annexin V staining of C4-2B cells 120 hr post ICK knockdown. 
C4-2B cells were stained with Annexin V 120 hr post transfection with scrambled control or siRNA-1.  (A) Representative FACS 
analysis of the Annexin V positive population at 96 hr.  (B) Graph represents mean + SD from 3 replicate experiments for 
viable cells.  *P<0.05 Student’s t-test. 
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Figure 5.4.  Western blot analysis of Cl-PARP 72, 96 and 120 hr following ICK knockdown in C4-2B cells. 
Cells were transfected with either scrambled control or siRNA-1 and analysed with Western blotting against ICK, Cl-PARP 
and actin (loading control) 72, 96 and 120 post transfection. 
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5.2.2 Identification of p53 as a novel downstream target of ICK. 
To understand how ICK regulated the survival of PCa cells, expression of a series of pro- and anti-
apoptotic proteins was explored using Western blot analysis following ICK knockdown.  The important 
characteristics of the selected proteins are summarised in table 5.1. 
CELL SURVIVAL-RELATED PROTEINS 
Protein Characteristics 
Focal adhesion 
kinase (FAK) 
 regulator of cell migration (Schaller, 2010) 
 expression increased in high-grade and metastatic PCa 
Protein kinase-C 
related protein 
kinase-2 (PRK2) 
 protein kinase involved in cell-cell interaction (Mukai, 2003) 
p53 
 tumour suppressor protein 
 acts as a transcription factor regulating the expression of many genes in 
response to cellular stressors such as, radiation, hypoxia, growth factor 
withdrawal and cytotoxic drugs (Meek, 2004) 
 deletions at the p53 gene locus reported in 25-40% of PCa  
 lesions in the germ-line in 5-40% of PCa patients (Barbieri et al., 2013) 
p21 
 cyclin-dependent kinase inhibitor 
 downstream target of p53 
 DNA damage-induced p53-activated p21 inhibits cyclin-dependent 
kinases (cdks) during the G1 phase of the cell cycle and results in cell 
cycle arrest (Slee et al., 2004), (Weinberg and Denning, 2002) 
 mutations in p21 rarely cause tumours (Weinberg and Denning, 2002) 
p38 
 MAP kinase 
 activated by extracellular stimuli including growth factors 
 involved in inflammation, cell growth, differentiation, cell cycle, cell 
death (Ono and Han, 2000) 
 expressed in basal and epithelial prostate cells 
 upregulated in poorly differentiated tumours (Koul et al., 2013) 
c-Jun 
 MAP kinase 
 implicated in cell survival signalling. 
 reduced c-Jun expression associated with development of CRPC in mice 
(Hubner et al., 2012) 
Table 5.1.  Summary of cell survival–associated proteins examined in this study. 
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Apart from a slight decrease in the level of phosphorylated p38 and c-jun, the majority of the 
proteins remained unchanged after knockdown of ICK (figure 5.5).  However, the level of p53 
protein, which represents the most important regulator of cell survival in both normal and cancer 
cells, was found to be significantly induced by ICK knockdown. 
 
 
 
Figure 5.5.  Western blot analysis of cell survival proteins in C4-2B cells following ICK knockdown.   
(A) C4-2B cells were transfected with either scrambled control or siRNA-1, lysed 72 hr later.  Twenty microlitres of total cell 
lysate was analysed with Western blotting against ICK, phospho- FAK, PRK2, phospho-c-Jun, phospho-p38, p53 and actin 
(loading control).  (B) Graph represents mean + SD from 3 replicate measurements of p53 protein following ICK 
knockdown. *P<0.05 Student’s t-test. 
 
5.2.2.1 ICK regulates expression of p53 and p21 in prostate cancer cells 
Since p53 induces cellular apoptosis through induction of p21 protein, Western blotting was 
performed to investigate if ICK also regulates the level of p21 protein in PCa cells.  Similar to p53, in 
C4-2B cells, knockdown of ICK was also found to induce p21 level, suggesting that ICK functions as a 
suppressor of the p53/p21 signalling pathway (figure 5.6A and B).  Furthermore, a consistent and 
statistically significant reduction in p53 and p21 protein expression was also observed in C4-2B cells 
overexpressing the ICK protein (figure 5.6C-E).  These findings provide strong evidence that ICK 
regulates PCa cell survival through modulation of the p53/p21 pathway.   
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Figure 5.6.  Western blot analysis of p53 and p21 following ICK knockdown and overexpression in C4-2B 
cells. 
(A) Cells were transfected with either scrambled control or RNA-1, lysed 72 hr later and 20 µL of total cell lysate was 
analysed with Western blotting against ICK, p53, p21 and actin (loading control).  (B) Graph represents mean + SD from 3 
replicate measurements of p21 protein following ICK knockdown. (C) Cells were transfected with either pCMV6-GFP or 
pCMV6-ICK-GFP, lysed 72 hr later and 20 µL of total cell lysate was analysed with Western blotting against ICK, p53, p21 
and actin (loading control) . (D) Graph represents mean + SD from 3 replicate measurements of p53 protein following ICK 
overexpression.  *P<0.05 Students t-test.  (E) Graph represents mean + SD from 3 replicate measurements of p21 protein 
following ICK overexpression.  *P<0.05 Student’s t-test. 
 
To investigate how ICK regulates the p53/p21 pathway, C4-2B cells transfected with either 
scrambled control or siRNA-1 were collected 72 hr post transfection.  Changes in p53 expression 
were investigated at the mRNA level in triplicate experiments using qRT-PCR.  As shown in figure 5.7, 
the level of p53 mRNA was unaffected by knockdown of ICK.  Similarly, p53 mRNA level was 
unchanged when C4-2B cells were transfected with either the empty vector (pCMV6-GFP) or ICK 
overexpression vector (pCMV6-ICK-GFP), suggesting that the effect of ICK on p53 protein expression 
is not mediated through regulation of p53 mRNA expression.   
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Figure 5.7.  qRT-PCR analysis of p53 mRNA following ICK knockdown and overexpression in C4-2B cells. 
Comparison of p53 mRNA level in C4-2B cells 72 hr following transfection with (A) scrambled control, siRNA-1, (B) pCMV6-
GFP or pCMV6-ICK-GFP.  Graphs represents mean + SD from 3 replicate experiments. 
 
 
5.3 Discussion 
In this study, it has been demonstrated for the first time that ICK expression is crucial for the survival 
of PCa cells, possibly through the regulation of the p53/p21 signalling pathway.  Although ICK has 
not been reported to regulate cell viability, in PCa cells, knockdown of ICK was found to increase the 
percentage of apoptotic population and a concomitant increase in Cl-PARP.  However, significant 
induction of apoptosis was observed only 96 hr after the transfection of siRNA-1.  Since an almost 
complete knockdown of the ICK protein was observed within 48 hr of the transfection, this 
observation suggested that inactivation of ICK does not lead to an immediate induction of apoptosis.   
PCa cells are highly resistant to chemotherapy-induced apoptosis.  Deregulation of pro or anti-
apoptotic signalling pathways have been proposed as the underlying mechanisms.  One of the best 
studied pathways is the p53/p21 signalling cascade, which is frequently inactivated in different 
cancers.  The finding that p53/p21 expression is suppressed by ICK in PCa cells suggests that 
aberrant expression of ICK may also contribute to p53 inactivation in cancer cells, leading to 
suppression of apoptosis.  Although Western blotting was performed with the stable ICK 
overexpressing HPr-1 cells, p53 was undetectable due to the fact that the cells were immortalised 
with the HPV E6 protein, which led to degradation of endogenous p53 protein.  However, unlike the 
EGFR, p53 mRNA was not affected by ICK knockdown, suggesting that ICK regulates p53 through 
post-translational modifications.  Currently, it is unclear whether ICK phosphorylates p53 and 
modulates its protein stability, since no consensus ICK phosphorylation site can be found in the p53 
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protein sequences.  However, it is worth noting that among the PCa cell lines examined in this study, 
ICK level was found to be lower in cell lines that carry p53 mutation (DU145) or deletion (PC-3), 
suggesting that ICK may be less essential in cells where p53 has been inactivated.   
In summary, the simultaneous induction of the p53/p21 pathway and apoptosis after ICK knockdown 
suggests that ICK may play an important role in regulating cell viability of PCa cells. 
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Chapter 6.0 General discussion 
The main aim of the current study was to understand the function and mechanisms of ICK in the 
growth and survival of PCa cells.  By screening a panel of proteins known to play roles in regulation 
of (1) cell proliferation and (2) cell survival, the results of this study have for the first time identified 
two novel downstream effectors regulated by ICK in PCa cells.   
 
Following ICK knockdown in C4-2B cells, there were significant changes in the level of epidermal 
growth factor receptor (EGFR) mRNA and protein.  EGFR is a cell surface receptor which, when it 
binds to extracellular ligands such as EGF, activates signalling cascades which include the mitogen-
activated protein (MAPK) and the phosphatidylinositide 3-kinase (PI3K) pathways through the 
cytoplasmic domain of the receptor (Dhillon et al., 2007).  Phosphorylation of specific tyrosine 
residues following ligand binding allows proteins such as growth factor receptor bound protein-2 
(GFRB2) to dock with the receptor and form a GFRB- son of sevenless complex which in turn activates 
Ras, followed by Raf, mitogen- activated protein kinase kinase (figure 6.1).  Aberrant activation of 
EGFR through overexpression, gene amplification as well as mutation has been shown to correlate 
with PCa disease progression.  EGFR expression was found to be upregulated in low androgen 
environments and is suggested to play a role in the development of CRPC (Traish and Morgentaler, 
2009).  Since ICK has also been shown to be upregulated in PCa, it is possible that ICK may contribute 
to the EGFR upregulation observed in the tumour.   
 
The results of the luciferase dual reporter assay outlined here imply that ICK regulates EGFR 
expression via the promoter region of the gene.  The promoter region of EGFR is approximately 670 
bp containing binding motifs for 9 transcription factors including max1, p53, STAT3 and c-Myc 
(GeneCards, 2014).  Moreover, Wu et al. (2012) reported that ICK deficiency causes growth 
retardation, cell cycle delay and down regulation of mTORC1 activity in intestinal epithelial cells in 
vitro.  The group also identified a phosphorylation site on mTORC1 which could bind ICK.  c-Myc is a 
specific downstream target of activated mTORC1 (Fu et al., 2009) and thus provides a possible 
linkage between ICK and the regulation of EGFR transcription (figure 4.1 and 6.3). 
The mTORC1 complex is also activated by EGFR via the PI3K/Akt pathway and regulates protein 
synthesis and ribosome biosynthesis ultimately leading to cell growth and proliferation (Populo et 
al., 2012) (figure 6.1).  In addition, the MAPK kinase pathway has previously been shown to be 
upregulated in primary and metastatic PCa and that activation of this pathway can accelerate cancer 
progression when coupled with PTEN loss (Mulholland et al., 2012).  Furthermore, cross-talk 
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between the MAPK and the PI3K/Akt pathway has been identified.  Activation of Ras by PI3K 
stimulates the pathway whereas inactivation of Raf by Akt reduces activity of the pathway 
(Carracedo and Pandolfi, 2008).  These data suggest that mTORC1 could be a central regulator for 
cell growth and proliferation (figure 4.1) integrating cellular responses to several signalling pathways 
including ICK.  Nevertheless, this effect of ICK on EGFR induction is not restricted to cancer cells, as 
similar changes in EGFR expression was also observed in HPr-1 cells overexpressing the ICK protein.  
It is worthwhile noting that ICK expression is responsive to androgen receptor activation.  The 
minimal ICK promoter contains consensus motifs for FOX (forkhead box) A1 and FOXA2 and β-
catenin/TCF7L2 transcription factors (Sturgill et al., 2010).  The FOXA1/androgen receptor complex 
regulates prostate cell gene expression and postnatal development (Augello et al., 2011) but may 
also influence tumour growth and hormone responsiveness in PCa.  Recent findings suggest FOXA1 
overexpression as a novel mechanism inducing castration resistance in PCa (Gerhardt et al., 2012).  
Clearly ICK expression may be an important component in the cellular response to androgen 
stimulation and therefore prostate cell growth, development and tumorigenesis.  Since ICK is 
frequently overexpressed in PCa tissues when compared to the normal prostate, it is therefore 
worthwhile to further investigate whether aberrant ICK expression may play a promoting role in the 
development and progression of PCa.   
 
 
Figure 6.1.  EGFR-MAPK signalling cascade. 
Signal transduction triggered by EGF binding to a 
cell surface receptor and finishing with the 
activation of the transcription factor c-Myc in 
the nucleus.  “P” represents phosphate groups.  
Figure adapted from (Schmidt, 2006) and (Davis 
et al., 2014). 
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Apart from regulating EGFR, the current experiments demonstrated that p53 protein levels 
increased following ICK downregulation (chapter 5.0), and were associated with onset of apoptosis.  
p53 is a tumour suppressor which acts as a transcription factor regulating the expression of a large 
network of genes in response to cellular stress (Meek, 2004).  In healthy cells p53 is regulated by 
mouse double minute 2 homlog (MDM2) which binds to the transactivation domain of p53 and 
inhibits its interaction with the transcriptional apparatus (Meek, 2004).  The levels of p53 increase 
following stress primarily due to post-translational modifications for example, phosphorylation or 
acetylation, which increase the stability of the protein (Slee et al., 2004).  Phosphorylation of p53 by 
proteins such as ataxia telangiectasia mutated (ATM) and alternative reading frame (ARF) tumour 
suppressor protein cause activation of p53 which allows for subsequent phosphorylation and 
inhibition of MDM2 binding (figure 4.2, (Meek, 2004).   
 
The lack of changes in p53 mRNA levels after ICK knockdown suggested that the induction of p53 
protein may also be a result of post translational modification (i.e.  increased half-life of the protein) 
(Oren, 1999), although additional experiments are needed to confirm this hypothesis.  The 
concomitant induction of p21 strongly suggested that ICK knockdown led to activation of the 
p53/p21 pathway as p21 is a direct downstream target of p53 which, when activated, results in cell 
cycle arrest (Slee et al., 2004) and cellular apoptosis.  The results of this study were consistent with a 
previous report, which showed that knockdown of ICK leads to induction of p21 expression in 
intestinal epithelial cells (Fu et al., 2009), an effect the authors attributed to decreased levels of c-
Myc.  Following DNA damage, p53-activated p21 inhibits the functions of cyclin dependent kinases 
during the G1 phase of the cell cycle as depicted in figure 6.2(Weinberg and Denning, 2002).  This 
may lead to G1 phase cell cycle arrest, DNA repair or apoptosis.  In PCa cells, the activation of the 
p53/p21 pathway following ICK knockdown appeared to induce cellular apoptosis, as evidenced by 
the increase in the annexin V positive cell population and in Cl-PARP protein levels.  Cell cycle arrest 
may have also happened in the early stage of the ICK knockdown.  Nonetheless, the current findings 
reveal p53/p21 as a novel downstream pathway regulated by ICK in PCa cells as summarized in 
figure 6.3. 
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6.1 Conclusion and future directions 
The current study not only demonstrated for the first time that ICK regulates the survival of PCa 
cells, but also discovered the important role of ICK in regulating the expression of EGFR and p53, two 
key proteins that regulate the growth and survival of normal and cancer cells (figure 6.3). 
Further studies are required to elucidate how ICK regulates EGFR and p53 signalling pathways.  In 
particular, additional experiments are needed to determine the proteins (including transcription 
factors) targeted by ICK activity.  One approach would be a characterisation of the ICK-dependent 
phosphoproteome (Rogne and Tasken, 2013).  PCa cells would be exposed to different stable isotope 
labelled amino acids in cell culture allowing cellular proteins to incorporate the label.  Tandem mass 
spectrometry would subsequently be used to identify phosphoserine, phosphothreonine, and 
phosphotyrosine-containing peptides and their parent proteins.  This type of large-scale 
identification and quantification of phosphorylation events triggered by ICK activity could identify 
unique phosphoprotein targets and novel phosphorylation sites on known protein targets.  A similar 
Figure 6.2. p53/p21 signalling. 
p53 signalling pathway in response to cellular stressor.  
Activator refers to proteins such as ATM and ARF.  “P” 
refers to phosphorylation.  Figure adapted from (Meek, 
2004). 
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approach perhaps preceded by immunoprecipitation could be used to determine whether ICK 
regulates p53 protein through phosphorylation. 
 
The therapeutic benefits of standard chemotherapy regimens are limited in patients with advanced 
PCa and the focus has progressed to inhibition of key elements of regulator pathways in PCa cells.  
The current study emphasises the importance of ICK in PCa cell biology and its potential utility as a 
target for disruptive treatment.  The concept is supported by the study of (Haggarth et al., 2011) 
who investigated expression of several biomarkers for PCa using tissue arrays.  They found over 
expression of ICK was a diagnostic tool for detection of PCa with 97% accuracy. 
 
One approach to target ICK would be a small molecule inhibitor of ICK enzyme activity.  None are 
currently available but small molecule inhibitors which inhibit key receptor tyrosine kinases 
(including EGFR) have been successfully introduced to treat various cancers, including breast and 
colorectal cancer.  These molecules tend to be competitive inhibitors of ATP binding at the catalytic 
domain of the enzyme and have limited specificity.  Recently compounds which bind outside the 
ATP-binding site and modulate kinase activity by allosteric mechanisms have been developed.  
Inhibitors belonging to this category exhibit a high degree of kinase selectivity because they exploit 
binding sites and regulatory mechanisms that are unique to a particular kinase.  Inhibitors of ICK 
could be designed and developed using methods such as high-throughput screening using 
biochemical or cellular assays, analogue synthesis, structure-guided design and fragment-based 
assembly strategies to target similar allosteric regulatory sites (Zhang et al., 2009). 
 
The data presented demonstrated that ICK expression could be inhibited by siRNA and that this was 
associated with decreased expression of EGFR and apoptosis.  Tissue selective delivery systems are 
now under development which could target ICK siRNA to PCa cells to initiate this effect in vivo.  
Nucleic acid aptamers are short single-stranded nucleic acids which fold into complex 3D shapes 
with pockets and clefts for binding of small molecules, large proteins and even whole cells (Aaldering 
et al., 2015).  These characteristics make aptamers an attractive platform for drug delivery including 
siRNA.  Some progress has been made using this technique for treatment of PCa.  Wu et al. (2011) 
used aptamer conjugation targeting prostate-specific membrane antigen as a tissue-specific 
intracellular delivery carrier of tumour suppressor microRNA to PCa cells.  This resulted in induction 
of cancer cell death.  A similar approach could target ICK siRNA to PCa cells in vivo. 
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Recent approaches have used newly developed agents to target signaling pathways activated in 
advanced prostate cancer including the Akt/mTOR pathway (rapamycin and related compounds) and 
MAPK signaling pathways (kinase inhibitors).  Results from studies in genetically engineered mutant 
mice and in human clinical trials suggest that the agents may not be effective in isolation and 
combination therapy using inhibitors of multiple signalling pathways potentially in conjunction with 
chemotherapy may be more effective.  Certainly combination therapy blocks castration-resistant 
prostate cancer in mice (Kinkade et al., 2008).  The development of ICK inhibitors would add another 
significant agent for this type of therapy. 
In summary the findings reported in this thesis will further strengthen the prognostic and 
therapeutic potentials of targeting ICK in the treatment of PCa.   
 
 
Figure 6.3.  Summary of the novel ICK downstream targets identified in this study. 
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